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ABSTRACT 
A study has been made of the secretory response and the electrical 
response (a hyperpolarization followed by a depolarization) mediated 
by dopamine receptors of the cockroach (Nauphoeta cinerea Olivier) 
salivary gland in- vitro. 
Receptor classification 
The selective D1 agonists fenoldopam and SK38393, and the selective 
D2 agonists LY163502 and quinpirole induced, in descending order of 
potency, secretion and a concomitant electrical response from the 
acinar cells. The secretory and electrical responses to dopamine 
were found to be antagonised by, in descending order of potency, 
chlorpromazine (a non - selective dopamine antagonist), SCH23390 (a 
selective D1 antagonist), haloperidol and metaclopramide (selective 
D2 antagonists). Another D2 antagonist (p)sulpiride and the highly 
selective D2 antagonist domperidone did not inhibit either the 
secretory or electrical responses. These results taken together 
suggest that the receptor mediating the secretory and electrical 
response are the same, and analogous to the mammalian D1 sub -type. 
This suggestion is strengthened by the fact that SCH23390 inhibited 
the secretory and electrical response to all the selective agonists, 
while (p)sulpiride did not. 
Although domperidone did response to 
dopamine, three other actions were observed: one, post- synaptic, 
led to the potentiation of the hyperpolarization; this action was 
shared by (p)sulpiride. A separate post- synaptic action resulted 
in the inhibition of the depolarizing phase of the response. 
Finally a presynaptic action led to the abolition of the response to 
nerve stimulation. 
Effects of the calmodulin antagonists W7 and calmidazolium 
In an attempt to investigate the role of calmodulin in stimulus - 
secretion coupling within the salivary gland, the actions of two 
calmodulin antagonists, W7 and calmidazolium, were studied. In 
high concentrations, but within the range in which they are known to 
inhibit calmodulin, W7 and calmidazolium were found to inhibit 
dopamine- induced secretion and hyperpolarize the acinar cells. The 
hyperpolarization was not inhibited by SCH23390, and resulted from 
an increase in cytosolic free calcium, released from the same source 
as that accessed by dopamine. Lower concentrations of these two 
antagonists caused submaximal secretion and potentiated dopamine - 
induced hyperpolarizations. An interpretation of these results is 
that calmodulin promotes secretion, and exerts a negative control on 






I A study has been made into the pharmacology of the dopamine 
receptors of the cockroach salivary gland. 
II An historical account is given in Chapter I of the secretory 
and electrical responses of the salivary gland to dopamine. 
The electrical response consists of a hyperpolarization which 
is occasionally followed by a depolarization. It has been 
suggested previously that secretion, the hyperpolarization 
and the depolarization might be mediated by three separate 
receptors. 
III The subclassification of dopamine receptors is discussed in 
Chapter II. 
IV In Chapters III to V an account is given of the effects of 
antagonists on the three responses to nerve stimulation and 
dopamine, and the ability of agonists to mimic dopamine. 
The antagonists used were: chlorpromazine (non -selective), 
SCH23390 (selective for D1 receptors), haloperidol, 
metoclopramide, domperidone and ( ±) sulpiride (all four 
selective for D2 receptors). The agonists used were: 
fenoldopam and SKF38393 (selective for D1 receptors), and 
LY163502 and quinpirole (selective for D2 receptors). 
V Chapter III describes a study of fluid secretion. Secretion 
was stimulated by addition of agonists to the superfusate. 
Secretory rates were measured before and after a standard 
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30 min exposure to the antagonists. KDs were estimated by 
"three point assay ". Because the antagonists did not always 
equilibrate the KDs obtained should be regarded as apparent 
values. 
VI Chlorpromazine, SCH23390, haloperidol and metoclopramide 
inhibited dopamine- induced secretion with KDs of 0.12µM, 
2.2µM, 17.4µM and 1.2mM, respectively. Domperidone and 
( ±)sulpiride failed to inhibit secretion. 
VII Fenoldopam, SKF38393 and quinpirole induced secretion. 
Within a factor of three the minimum effective concentrations 
were 4.8µM, 47µM and 732µM, respectively. 
VIII The responses to all three agonists were inhibited by 
SCH23390, not by ( ±)sulpiride. 
IX The rank order of potency of agonists and antagonists at the 
secretory receptor supports the idea that this receptor is 
similar to the mammalian D1 sub -type, but distinct from the 
D2 sub -type. 
X Chapter IV is devoted to the pharmacology of the receptor 
mediating the hyperpolarization to dopamine and nerve 
stimulation. Membrane potentials of individual acinar cells 
were measured with intracellular electrodes. Responses to 
agonists were usually induced by local application via 
pressure ejection from a microelectrode with a broken tip. 
Occasionally agonists were added to the superfusate. 
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Responses to nerve stimulation were induced by applying 
trains of stimuli at 20Hz. The protocol for studying 
antagonists was generally as described for the study of the 
secretory receptors. The effects of antagonists on the 
responses to dopamine and nerve stimulation were studied in 
parallel. Responses to dopamine, D, and nerve stimulation, 
N, were evoked at intervals of 90s with the sequence D1, D2, 
N. D1 and D2 represent different effective concentrations. 
The use of two concentrations allowed estimates of the KD of 
antagonists by "three point assay ". No quantitative 
analysis of the effects of antagonists on nerve stimulation 
was attempted. 
XI Responses to nerve stimulation were inhibited by 
chlorpromazine, SCH23390, haloperidol and metoclopramide. 
These the hyperpolarization 
to dopamine with KDs of: chlorpromazine 0.2µM, SCH23390 
4.1µM, haloperidol 3.3µM and metoclopramide 265µM. In 
contrast ( ±)sulpiride and domperidone potentiated the 
hyperpolarization to dopamine (see XVII and XVIII). 
XII Fenoldopam, SKF38393, LY163502 and quinpirole induced a 
hyperpolarization with a minimum effective concentration, 
within a factor of 2, of 3.3µM, 5.3µM, 44µM and 100µM 
respectively. 
XIII The responses to all four agonists were inhibited by 
SCH23390, but not by ( ±)sulpiride. 
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XIV The rank order of potency of agonists and antagonists 
suggests that the same receptor subserves secretion and the 
hyperpolarization. 
XV Chapter V describes an investigation into the depolarizing 
component of the electrical response. The methods used were 
as described for Chapter IV, but detailed quantitative 
results were not obtained. Fenoldopam, SKF38393, LY163502 
and quinpirole induced a depolarization. Chlorpromazine, 
SCH23390, haloperidol and metoclopramide were effective 
antagonists of the depolarization to dopamine and nerve 
stimulation. The range of concentrations over which the 
antagonists inhibited the depolarization were the same as for 
the hyperpolarization. The results do not support the idea 
that separate receptors mediate the hyperpolarizing and 
depolarizing components of the response. 
XVI In contrast to its effect on the hyperpolarization, 
domperidone inhibited the depolarization to dopamine. This 
finding might be taken to support the idea that different 
receptors mediate the hyperpolarization and depolarization, 
but the absence of an effect on the depolarization of 
( ±)sulpiride and the inhibition of the depolarization by 
SCH23390 argue against the idea that the receptor subserving 
the depolarization is a D2 receptor. The possibilities 
therefore arise that this receptor is a hitherto unknown sub- 
type, or that domperidone acts at a level beyond the dopamine 
receptor. 
5 
XVII Chapter VI describes a further investigation into the 
pharmacology of domperidone. As mentioned above domperidone 
potentiated the hyperpolarization to dopamine. The 
hyperpolarization induced by local application of 5 -HT was 
also potentiated by domperidone. It is known that 5 -HT acts 
on different receptors (Bowser -Riley et al, 1978). 
Domperidone did not however potentiate the secretory response 
to dopamine. ( ±)Sulpiride was also tested against the 
dopamine- induced hyperpolarization and secretion, and acted 
like domperidone. These results are consistent with the 
idea that the potentiation of the hyperpolarization to 
dopamine by domperidone and ( ±)sulpiride occurs beyond the 
point of receptor activation. 
XVIII In Chapter VII a description is given of a study of the role 
of calmodulin secretory and electrical responses of 
the salivary gland to dopamine. The effects of two 
calmodulin antagonists, W7 and calmidazolium, were 
investigated. 
XIX Low concentrations of W7 and calmidazolium induced submaximal 
secretion. At higher concentrations the rate of secretion 
fell and was not increased by the addition of dopamine. 
XX Low concentrations of W7 and calmidazolium potentiated the 
hyperpolarization to dopamine. Higher concentrations of W7 
and calmidazolium induced a hyperpolarization which did not 
decline during prolonged exposures to these substances. The 
hyperpolarization to W7 was not inhibited by SCH23390, in a 
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concentration which blocked matching responses to dopamine. 
This strongly suggests that the hyperpolarization to W7 and 
calmidazolium occurs independently of activation of the 
dopamine receptor. 
XXI After the preparation had been exposed to calcium free 
solution for 10 min, the hyperpolarization to W7 declined 
during prolonged exposure. No response was obtained to W7, 
in the absence of added calcium, after prior exposure of the 
preparation to dopamine in calcium free solution. Prior 
exposure of the preparation to W7, in the absence of added 
calcium, inhibited the response to dopamine. The results 
indicate that the hyperpolarization is calcium- dependent and 
that W7 and calmidazolium appear to release calcium from the 
same source as does dopamine. 
XXII A model is presented which accounts for simultaneous 
inhibition of secretion and activation of the 
hyperpolarization. In a qualitative way, the model predicts 
oscillations in the concentration of intracellular calcium in 
situations in which they have been observed. 
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THE COCKROACH SALIVARY GLAND 
Structure of the salivary gland 
The cockroach salivary gland is a bilateral structure lying on the 
ventral surface of the crop and consists of groups of acini and two 
reservoirs. Two pairs of ducts, one from the acini and one from 
the salivary reservoirs, join to form the main duct which opens in 
to the hypopharynx. The acini are composed of three layers: an 
external envelope, a membrane contiguous with the secretory ducts 
and, sitting between these, the acinar cells (for review see Bowser - 
Riley, 1978a). Kupffer (cited by Bowser -Riley, 1978a) 
distinguished two cell types, peripheral and central. The 
peripheral cells lie beneath the basement membrane, they are oval or 
pyramidal in shape and have an intracellular ductule which is 
continuous with the lumen of the gland. These cells contain a 
single nucleus, mitochondria and ribosomes, but no endoplasmic 
reticulum or secretory vesicles (Bland and House, 1971; Kessel and 
Beams, 1963). The central cells form the bulk of the acinus, 
contain endoplasmic retículum, large secretory vesicles and a 
mucoprotein (Bland and House, 1971). The central cells are joined 
by septate desmosomes and have microvilli near the junction of the 
cell with the beginning of the duct. Although the majority of the 
ducts are composed of non - secretory cells, duct cells near the acini 
have large vesicles of dense granular material containing 
sialoglycans and a high tryptophan concentration. 
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Innervation 
The salivary gland of Nauphoeta cinerea receives two sources of 
innervation, the principle source being from the suboesophageal 
ganglion. In addition a limited innervation, particularly of the 
acini lying adjacent to the reservoir ducts, arises from the 
somatogastric nerve (Bowser -Riley, 1978a). Lateral groups of acini 
are innervated by the ipsilateral duct nerve, while central cells 
receive their innervation from both duct nerves. Three types of 
axons have been distinguished in the salivary gland (Maxwell, 1978); 
one, clear, containing no vesicles, while the other types, A and B, 
do contain vesicles. Type A axons are more numerous and innervate 
cells throughout the acinus, while type B axons innervate only the 
peripheral cells underneath the basement membrane. 
The neurotransmitter 
It was initially proposed (House, 
transmitter at this synapse. 
indicated that a catecholamine, not 
terminals (Bland et al, 1973). 
1973) that 5 -HT might be the 
However microspectrofluorimetry 
5 -HT, was present in the nerve 
Radiochemical assay and HPLC 
identified the catecholamine as dopamine (Fry et al, 1974; Kapoor 
et al, 1983). It should however be noted that dopamine, 
adrenaline, noradrenaline and 5 -HT all evoke secretion and an 
electrical response from the acinar cells (Bowser -Riley and House, 
1976; Bowser -Riley et al, 1978; Breward et al, 1980; Ginsborg et 
al, 1976b; House, 1973). 
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Secretion 
It has been suggested that the peripheral cells may be involved in 
the production of dilute watery secretion (Cholodkowsky, 1881; 
Hofer, 1887; Lebedeff, 1899; all three cited by Bowser -Riley, 
1978a; Bland and House, 1971), while the central cells are known to 
secrete mucin and amylase (Bland and House, 1971). In addition 
maltase, invertase and protease have been found in the secretion, 
although the cells of origin have not been identified (Bland and 
House, 1971). The rate of secretion is dependent on the 
concentration of sodium, potassium, calcium and chloride ions. The 
sodium ions are thought to be the driving force for water movement, 
while the potassium ions have been presumed to be necessary for the 
normal functioning of the sodium /potassium pump. However, though 
the rate of secretion is dependent on the external chloride 
concentration, distributed passively 
across the membrane, and thus unlikely to have an active role in 
the secretory response. In contrast, calcium appears to play an 
essential role in the induction of the secretory response, as 
substitution of the external calcium by magnesium reduces 
consecutive responses to dopamine (Smith and House, 1979; Gray and 
House, 1982). 
The electrical response 
Nerve stimulation and dopamine evoke a hyperpolarization of the 
salivary gland which is occasionally followed by a depolarization 
(House, 1973; Ginsborg et al, 1974; Ginsborg et al, 1976a; 
Bowser -Riley et al, 1978). The cells in the acinus are 
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electrically coupled, and dopamine induces a hyperpolarization of 
both central and peripheral cells (House, 1975). The 
hyperpolarization results from an increase in potassium conductance 
(House, 1973; Ginsborg et al, 1974) which, like secretion, has been 
shown to be calcium- dependent, consecutive responses being reduced 
and eventually abolished under conditions where the external calcium 
concentration is near zero (Ginsborg et al, 1980). Support for 
this conclusion arises from the fact that the calcium ionophore 
A23187 alone induces a hyperpolarization (Mitchell and Martin, 
1980). The conductance underlying the depolarization is not yet 
known, although it has been suggested that different receptor sub- 
types mediate the depolarizing and hyperpolarizing components of the 
response respectively (Ginsborg and House, 1976). 
Signal transduction 
Until the early 1980's, with the exception of the role of calcium, 
little was known about signal transduction in the cockroach salivary 
gland. However more recent studies have shown that dopamine 
induces an increase in cytoplasmic c -AMP levels, and it is clear 
that c -AMP is an intermediate in the secretory, but not the 
electrical response to dopamine (Gray et al, 1984; Grewe and 
Kebabian, 1982). This fact led to the suggestion that the 
secretory and electrical responses were mediated by different 
receptors (Gray et al, 1984). 
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DOPAMINE RECEPTOR SUB - CLASSIFICATION 
Mammalian systems 
The last twenty years have seen many advances in the knowledge of 
the function and pharmacology of dopaminergic systems. It is now 
apparent that there are at least two sub -types of dopamine receptor, 
namely D1 and D2. 
The early 1970's saw the first steps towards sub -division of the 
dopamine receptors following the discovery of a dopamine- sensitive 
adenylyl cyclase in neuronal tissue from the CNS (Brown and Mackman, 
1972; Kebabian et al, 1972). Subsequently the actions of a 
variety of dopamine agonists and antagonists on this system were 
found to correlate well with actions on physiological preparations 
(Clement- Cormier et al, 1974; Miller et al, 1974). The 
possibility of dopamine receptor sub - classification was first 
broached when the butyrophenone dopamine antagonists, in particular 
haloperidol, were found to be weak inhibitors of the dopamine- 
induced increase in c -AMP, relative to their effects in other 
functional models (Iversen, 1975; Snyder et al, 1975). In 
addition, a number of ergot derivatives were found to mimic the 
action of dopamine in the pituitary gland, whilst they inhibited the 
dopamine- induced adenylyl cyclase activity of the striatum without 
activating adenylyl cyclase in their own right (Kebabian et al, 
1977; Pieri et al, 1978). Thus dopamine receptors were sub- 
divided: on one hand those receptors positively coupled to adenylyl 
cyclase, which were named D1 receptors and those on the pituitary, 
originally thought to be without any influence on adenylyl cyclase, 
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which were named D2 receptors (Kebabian, 1978; Kebabian and Calne, 
1979; Spano et al, 1978). Later investigations showed that the D2 
receptors of the pituitary (Cote et al, 1982; Swennen and Denef, 
1982; De Camilli et al, 1979; Enjalbert and Bockaert, 1983) and 
striatum (Cooper et al, 1986; Onali et al, 1984; Stoof and 
Kebabian, 1981; Weiss et al, 1985; Saller and Sallama, 1986a) were 
in fact negatively coupled to adenylyl cyclase. However this may 
not be universally true. Initially central and peripheral dopamine 
receptors were presumed to be different and named D1 and D2 and DA1 
and DA2, respectively. However, as yet, no pharmacological 
distinction has been accepted. Thus the nomenclature has now been 
streamlined, with both central and peripheral receptors being 
classified as either D1 or D2. 
Dopamine receptors were also sub - divided with respect to their 
anatomical location. It was noted that dopamine receptors located 
pre - synaptically on nerve terminals (controlling dopamine synthesis 
and release), cell somata and dendrites (regulating impulse traffic 
along dopaminergic nerves) were more sensitive to dopamine agonists 
than post- synaptic dopamine receptors (Carlsson, 1975; Roth, 1979; 
Skirboll et al, 1979). In common with pre- synaptic receptors for 
other neurotransmitters, these have been termed autoreceptors 
(Carlsson, 1975). Subsequent pharmacological characterization of 
these receptors has shown that they are of the D2 sub -type. 
Although putative D2 autoreceptor selective agonists have been 
reported (Johansen and White, 1987), subsequent studies have shown 
no evidence of agonist selectivity for either the pre- or post - 
synaptic D2 receptors. 
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Pharmacological profile of D1 and D2 receptors 
Since the selective action of the butyrophenone dopamine antagonists 
for D2 receptors was first observed, a number of selective agonists 
and antagonists have come of age. For the sake of clarity the 
pharmacology of the two receptors will be discussed in relation to 
the action of the compounds used in the present investigation; 
namely SKF38393, fenoldopam (selective D1 agonists), quinpirole, 
LY163502 (selective D2 agonists), SCH23390 (a selective D1 
antagonist), haloperidol, metoclopramide, ( ±)sulpiride (antagonists 
selective for D2 receptors) and domperidone (highly selective for D2 
receptors). 
D1 Receptors 
Selective agonists SKF38393 was first synthesised in 1978 by 
Pendleton and co- workers and was found to dilate the renal artery. 
Further studies established that this compound had an atypical 
agonist profile at dopamine receptors. Thus SKF38393 was found to 
stimulate dopamine- sensitive adenylyl cyclase in the caudate nucleus 
but failed to induce emesis and did not inhibit dopamine turnover, 
or prolactin release (Setier et al, 1978). Following the sub- 
classification of the dopamine receptors by Kebabian and Caine 
(1979), it was proposed that SKF38393 was a selective Dl agonist 
(Stoof and Kebabian, 1981). Subsequent ligand binding studies 
revealed that SKF38393 has a much higher affinity for D1 as opposed 
to D2 receptors in the CNS (Anderson et al, 1985; Hyttel, 1983 & 
1984; Sibley et al, 1982b; O'Boyle and Waddington, 1987). In 
addition this compound has been shown to inhibit noradrenaline- 
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induced contractions of the rabbit splenic artery (Ohlstein et al, 
1984) and relax the dog mesenteric vascular bed (Hilditch and Drew, 
1985). It also stimulates adenylyl cyclase, and secretion from the 
parathyroid gland by activation of D1 receptors (Brown et al, 1980). 
In all D1 receptor models SKF38393 has been shown to be less potent 
than dopamine and it has been proposed as a partial agonist 
(Hilditch and Drew, 1985). In most D2 receptor models SKF38393 was 
found to be inactive. Thus it fails to inhibit tachycardia induced 
by sympathetic nerve stimulation; nor does it relax the 
sympathetically - induced contraction of the rat anococcygeus muscle 
(Hilditch and Drew, 1985). However Enjalbert and Bockaert (1983) 
showed SKF38393 to bind to D2 receptors of the rat pituitary but 
with a low affinity (RD = 1mM). 
Fenoldopam (SKF82526) is a close analogue of SKF38393 and, like 
SKF38393, it has been shown to be a selective D1 agonist (Weinstock 
et al, 1980). Thus it binds selectively to D1 receptors in the CNS 
and periphery (O'Boyle and Waddington, 1987; Niznik et al, 1988), 
activates dopamine- sensitive adenylyl cyclase in the CNS and 
periphery (Weinstock et al, 1980; Sigala, 1989), and relaxes the 
rabbit splenic artery (Ohlstein et al, 1984) and dog mesenteric 
vascular bed (Hilditch and Drew, 1985). Fenoldopam is more potent 
an agonist than SKF38393, but is still consistently less potent than 
dopamine. As regards an action at D2 receptors, little information 
is available. However it is clear that fenoldopam shows only low 
affinity for D2 receptors of human caudate putamen membranes 
(O'Boyle and Waddington, 1987), and as an agonist in functional 
models it fails to inhibit prolactin release in the dog (Hahn et al, 
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1982), sympathetically - induced tachycardia in the cat and 
sympathetically - induced contractions of the rabbit anococcygeus 
muscle (Hilditch and Drew, 1985). 
Selective antagonists SCH23390 was proposed as the first 
selective D1 antagonist (Hyttel, 1983; Iorio et al, 1983). This 
compound was shown to inhibit dopamine - stimulated adenylyl cyclase 
activity with 2,000 times greater potency than it inhibited 
3H- spiperone binding to D2 receptors. It has since been shown that 
SCH23390 blocks D1 receptors of the parathyroid gland (Niznik et al, 
1986), and dopamine- induced relaxation of the rabbit splenic artery 
and dog mesenteric vascular bed (Hilditch and Drew, 1985). It does 
not raise prolactin levels in rats ( Iorio et al, 1983; Seller and 
Salama, 1986b) and does not block the inhibition of sympathetic 
nerve - induced tachycardia in the cat, or sympathetically mediated 
contractions of the rabbit anococcygeus muscle (Hilditch and Drew, 
1985). This suggests that SCH23390 does not posess significant 
affinity for D2 receptors. Consistent with these findings is the 
fact that SCH23390 displaces 3H- piflutixol from D1 receptors with a 
KD of 0.3µM whereas it displaces 3H- spiperone from D2 receptors in 
the striatum with a KD of 1.3µM (Boyce et al, 1985; Cross et al, 
1983; see also O'Boyle and Waddington, 1987). However SCH23390, 
in relatively low concentrations, has been shown to block the 
inhibition by dopamine of acetylcholine release from striatal 
slices, an event which is thought to be mediated by D2 receptors 
(Plantje et al, 1984b). 
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D2 receptors 
Selective agonists The first of the selective D2 receptor 
agonists was LY141865. Tsuruta et al (1981) established that this 
compound was a full agonist of D2 receptors in the intermediate lobe 
of the rat pituitary, which upon activation inhibit adenylyl cyclase 
and thus secretion of a -MSH. In contrast LY141865 did not activate 
the dopamine- sensitive adenylyl cyclase in the carp retina (Tsuruta 
et al, 1981). Subsequent investigations have shown that LY141865 
is an antagonist of 3H- spiperone binding to bovine pituitary 
membranes (Seeman et al, 1987), and, by activating pre - synaptic D2 
receptors, inhibits the release of nor -adrenaline from sympathetic 
nerve terminals in the cardiovascular system (Hahn et al, 1982). 
In the central nervous sytem LY141865 has been shown to be an 
agonist of post- synaptic D2 receptors in the nucleus accumbens 
(White and Wang, 1986). 
LY141865 has now been superseded by its active enantiomer quinpirole 
(LY171555), which has a four fold greater affinity for D2 receptors 
than its parent compound (Seeman et al, 1987). Quinpirole has now 
become the classical D2 receptor agonist, and more recent studies 
have shown that it inhibits transmission at the stellate ganglion 
(Sabouni et al, 1986), inhibits adenylyl cyclase in the rat anterior 
pituitary (Enjalbert and Bockaert, 1983), inhibits Ach release from 
the caudate putamen and inhibits dopamine turnover in the CNS 
(Foreman et al, 1989; Brown et al, 1985). It also slows the heart 
and relaxes vascular smooth muscle by inhibiting nor -adrenaline 
release through the activation of pre- synaptic D2 receptors on 
sympathetic nerve terminals (Hilditch and Drew, 1985). Although 
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quinpirole has a low affinity for D1 receptors in the CNS and 
periphery (Niznik et al, 1985), it has been reported to be a weak 
agonist of D1 receptors in the dog pancreas (Horiuchi et al, 1989). 
LY163502 is the latest addition to the line of selective D2 
agonists. Murray and Waddington (1989) have shown that this 
compound has a far greater affinity for D2 as opposed to D1 
receptors and it has subsequently been found to inhibit prolactin 
secretion, inhibit dopamine turnover in the CNS, induce emesis in 
the dog and inhibit ACh release from the caudate putamen (Foreman et 
al, 1989). 
Selective antagonists As mentioned above, butyrophenone 
dopamine antagonists, in particular haloperidol, were the first 
compounds identified as being selective for D2 receptors (Iversen, 
1975; Snyder et a1,1975). However haloperidol is not a highly 
selective antagonist having a KD at D1 receptors within an order of 
magnitude of that obtained at D2 receptors (Anderson et al, 1987; 
Hilditch and Drew, 1985; Seeman et al, 1987). Since these 
observations were made a number of antagonists showing a high degree 
of selectivity for D2 receptors have been introduced. 
( ±)Sulpiride was first proposed as a selective D2 antagonist by 
Jenner and Marsden (1981). Thus ( ±)sulpiride inhibits 3H- spiperone 
binding to pituitary membranes (Seeman et al, 1987; Enjalbert and 
Bockaert, 1983) and blocks dopamine- induced inhibition of adenylyl 
cyclase in the intermediate lobe of the rat pituitary gland 
(Munemura et al, 1980; Tsuruta et al, 1981). In addition 
( ±)sulpiride has been shown to block the dopamine- induced inhibition 
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of both tachycardia of the cat heart and contractions of the rabbit 
anococcygeus muscle evoked by stimulation of sympathetic nerves 
(Hilditch and Drew, 1985). It also inhibits binding to D2 
receptors and D2 mediated events in the CNS, including dopamine - 
induced inhibition of adenylyl cyclase (Hytell, 1983; Lacey et al, 
1987; Alkadhi et al, 1986; Stoof and Kebabian, 1981). It is 
clear that of the two enantiomers (- )sulpiride is more potent at D2 
receptors than is ( +)sulpiride (Sabouni et al, 1986; Tsuruta et al, 
1981; White and Wang, 1984; Seeman et al, 1987; Enjalbert and 
Bockaert, 1983; Alkadhi et al, 1986). The action of ( ±)sulpiride 
at D1 receptors is not so clear cut. Goldberg and Kohli (1983) 
suggested that ( +)sulpiride blocks D1 receptor mediated events in 
the cardiovascular system, while (- )sulpiride does not (see also 
Ohlstein et al, 1984). Subsequent investigations have established 
that this is also the case at other D1 receptors in the CNS and 
periphery (Niznik et al, 1988; Basse and Robie, 1984; Brodde, 
1982). However studies of other D1 receptors in the CNS and 
periphery have found little or no activity with either isomer 
(Anderson et al, 1985; Fleminger et al, 1983; Hilditch and Drew, 
1985). 
In 1979 Laduron and Leyson suggested that domperidone was a 
selective antagonist of D2 dopamine receptors in the rat CNS, as it 
displaced 3H- haloperidol binding in the striatum with far greater 
potency than it inhibited dopamine - stimulated adenylyl cyclase 
activity. This conclusion was supported by the fact that 
domperidone was a poor antagonist of dopamine- stimulated adenylyl 
cyclase activity in the retina of the guinea -pig and carp (Watling 
and Dowling, 1981). Subsequently domperidone has been shown to 
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have a high affinity for D2 receptors of the anterior pituitary 
(Sibley et al, 1982; Seeman et al, 1987), striatum (Kazmi et al, 
1986; Anderson et al, 1985) and to block dopamine- induced inhibition 
of nor -adrenaline release from sympathetic nerve terminals (Hilditch 
and Drew, 1985). In D1 receptor models domperidone, as mentioned 
above, has been found to be a poor antagonist. Thus it does not 
inhibit dopamine- stimulated adenylyl cyclase in retinal tissue 
(Watling and Dowling, 1981) or rat striatal homogenates (Flaim et 
al, 1985; Anderson et al, 1987), and does not inhibit dopamine - 
induced relaxation of the rabbit splenic artery, or vasodilation of 
the dog mesenteric vascular bed (Hilditch and Drew, 1985). In 
ligand binding studies it has been shown that domperidone has a very 
low affinity for D1 receptor binding sites (Anderson et al, 1987; 
O'Boyle and Waddington, 1984; Flaim et al, 1985) 
Metoclopramide is another selective D2 antagonist, but like 
haloperidol it does not lack activity at the D1 receptor. In 
ligand binding studies, metoclopramide has been shown to inhibit 
3H- spiperone binding to the anterior pituitary (Seeman et al, 1987) 
and to rat striatal membranes (O'Boyle and Waddington, 1984; 
Fleminger et al, 1983). In functional models metoclopramide has 
been found to block dopamine mediated inhibition of catecholamine 
release from sympathetic nerve terminals (Hope et al, 1978) and 
dopamine- induced inhibition of adenylyl cyclase in the rat pituitary 
(Munemura et al, 1980). In studies of D1 receptors metoclopramide 
failed to inhibit binding of selective ligands and, in 
concentrations up to 100µM, was without activity against dopamine- 
stimulated adenylyl cyclase activity in the rat striatum (Flaim et 
al, 1985; Fleminger et al, 1983; O'Boyle and Waddington, 1984). 
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In the periphery metoclopramide was found to inhibit fenoldopam- 
induced relaxation of the rabbit splenic artery (Ohlstein et al, 
1984), dopamine- evoked relaxation of the rabbit mesenteric artery 
(Brodde et al, 1981) and D1- mediated reduction in renal vascular 
pressure (Hahn et al, 1982) with KD's of approximately 5µM. 
However metoclopramide failed to antagonise dopamine- induced 
relaxation of the guinea -pig aorta (Cox and Ennis, 1979). 
Prototypical D1 and D2 receptor systems 
From the information presented above, one can define prototypical D1 
and D2 receptor systems on a functional and pharmacological basis. 
D1 receptors stimulate adenylyl cyclase; the consequential 
responses would be activated by the selective D1 agonists fenoldopam 
and SKF38393, but not the selective D2 agonist quinpirole. In 
turn, the responses induced by dopamine, fenoldopam and SKF38393 
would be blocked by the selective D1 antagonist SCH23390, but not by 
the selective D2 antagonists ( ±)sulpiride or domperidone. D2 
receptors inhibit adenylyl cyclase; consequential responses would 
be activated by quinpirole, but not by fenoldopam or SKF38393. In 
turn; the responses induced by dopamine and quinpirole would be 
blocked by the selective D2 antagonists ( ±)sulpiride and 
domperidone, but not by SCH23390. Haloperidol and metaclopramide 
would be expected to antagonise both responses to dopamine, but with 
greater potency with respect to the D2 receptor mediated event. 
The classical non - selective dopamine antagonists such as a- 
flupenthixol and chlorpromazine, would be expected to block both 
responses with equal potency. 
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Interactions between D1 and D2 receptors 
The analysis of the pharmacology of dopamine in some systems is not 
as clear cut as would seem from the information provided above, as 
it appears that in many cases both D1 and D2 receptors are present 
on the post- synaptic membrane. Stoof and Kebabian (1981) showed 
that dopamine- induced efflux of c -AMP from the rat striatum was 
inhibited by LY141865 through the activation of a post- synaptic D2 
receptor. More recently the stimulation of adenylyl cyclase 
activity in striatal homogenates by dopamine was found to be 
switched to an inhibitory effect in the presence of the D1 
antagonist SCH23390 and this effect was antagonised by ( ±)sulpiride 
(O'Boyle and Waddington, 1985). Such a relationship has also been 
proposed in the regulation of prolactin release from the anterior 
pituitary by dopamine (Treiman and Greengard, 1985). Thus dopamine 
inhibits adenylyl cyclase and secretion as does the selective D2 
agonist quinpirole , while the selective D1 agonist SKF38393 
activates adenylyl ayclase and induces secretion; these effects are 
blocked by selective D2 and D1 antagonists respectively ( Treiman and 
Greengard, 1985; Enjalbert and Bockaert, 1983; Sailer and Salama, 
1986a & b). 
Dopamine receptors in invertebrates 
Studies of the action of dopamine in invertebrates in the 70's and 
early 80's identified this substance as an important 
neurotransmitter both in the CNS and the periphery. In addition a 
number of dopamine receptor- mediated functions were shown to be 
dependent on an increase in cellular c -AMP levels, and at least four 
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dopamine receptor sub -types have been proposed in invertebrates (for 
review see Walker et al, 1980; Gospe Jr., 1983). However the 
majority of these studies preceded the introduction of selective 
agonists and antagonists, while others lacked sufficient 
pharmacological data for classification of the receptors. It is 
now however clear that receptors similar to the mammalian D1 and D2 
receptor exist together with three other sub -types. In 1985 Stoof 
et al characterized two dopamine receptors on the growth hormone 
producing cells of the snail (Lymnae stagnalis), one of which was 
similar to the mammalian D1 receptor and the other to the D2 
receptor. The D2 receptor subserved a hyperpolarization of the 
cells, which was the dominant event, a response which could be 
induced by the D2 agonist LY141865 and inhibited by the D2 
antagonists ( ±)sulpiride and YM09151 -2. The D1 receptor subserved 
a c -AMP dependent increase in the excitability of these cells, this 
effect being mimicked by the D1 agonist SKF38393 and antagonised by 
the D1 antagonist SCH23390. Thus it appears that these receptors 
interact to control growth hormone secretion in much the same way as 
D1 and D2 receptors regulate secretion from the anterior pituitary. 
A more recent study has now suggested that the D2 receptor on these 
growth hormone secreting cells may be different from D2 receptors in 
the mammal as domperidone does not act as an antagonist here and the 
selective D2 receptor agonist N -0437 is ineffective (Werkman et al, 
1987). The use of selective agonists and antagonists has also 
identified a D1 -like receptor on the locust (Locusta migratoría L.) 
salivary gland (Lafon -Cazal and Bockaert, 1983), the effects of 
dopamine being mimicked by SKF38393 and inhibited by a number of 
non - selective dopamine antagonists, but not by the selective D2 
antagonist domperidone. 
25 
Dopamine receptors distinct from either the mammalian D1 or D2 
receptor have been found in a number of preparations. Studies of 
the buccal -2 neurone and pedal giant neurone of Lymnae stagnalís 
(Audesirk, 1989) revealed a dopamine receptor which subserves a 
hyperpolarization. This response was not mimicked by selective D1 
or D2 agonists and was not inhbited by either selective or non- 
selective dopamine antagonists. In the cerebral and buccal ganglia 
of Limax maximus dopamine induces a feeding motor program, a 
response which was also induced by the D1 agonist SKF38393, but not 
inhibited by a range of neuroleptics (Wieland and Gelprin, 1983). 
In addition Orr et al (1987) characterized a dopamine- sensitive 
adenylyl cyclase system in the cockroach (Periplaneta americana) CNS 
whose pharmacology showed little if any similarity to that of either 
the D1 or D2 dopamine receptor. Thus the D2 agonist quinpirole 
induced c -AMP accumulation, whereas the D1 agonists fenoldopam and 
SKF38393 inhibited the response to dopamine. Furthemore the D1 
antagonists SCH23390 and SKF83566 had a greater affinity for the 
dopamine receptor than did the D2 antagonist ( ±)sulpiride, while 
haloperidol failed to inhibit the response to dopamine. 
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CHAPTER III 
CHARACTERIZATION OF THE SECRETORY RECEPTORS 
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INTRODUCTION 
It is now well established that secretion from the cockroach 
(Periplaneta americana and Nauphoeta cinerea) salivary gland is 
controlled by the suboesophageal nerve (Whitehead, 1970; Smith and 
House, 1977), the neurotransmitter at this synapse being dopamine 
(Bland et al, 1973; Fry et al, 1974; Kapoor et al, 1983). Little 
is known however about the target receptors, and as yet there have 
been no pharmacological investigations to determine whether or not 
they are similar to one or other of the mammalian sub -types of 
dopamine receptor, namely the D1 and D2 receptors. Moreover, and 
perhaps more importantly, comparison of the pharmacology of the 
receptors mediating secretion from and the hyperpolarization of the 
acinar cells, respectively, is required to address the conclusions 
of Gray et al (1984), who suggested that a different type of 
receptor was responsible for each event. 
In the present investigation the rank order of potency of the 
following antagonists was obtained against the secretory response to 
dopamine: SCH23390 (a selective D1 antagonist), domperidone, 
( ±)sulpiride, haloperidol and metoclopramide (selective D2 
antagonists) and chlorpromazine (a non - selective dopamine 
antagonist). Furthermore, the ability of two D1 receptor agonists, 
SKF38393 and fenoldopam, and two D2 receptor agonists, quinpirole 
and LY163502, to induce secretion from the gland was studied, 
together with the effects on the responses obtained of the D1 




Cockroaches (Nauphoeta cinerea, Olivier) were reared in glass 
aquaria and provided with rat cake, fruit and water ad libitum. 
Bathing solution 
Cockroaches, during dissection, and the salivary apparatus, after 
removal from the animal, were bathed in a solution of the following 
composition (mM): NaC1, 160; KC1, 1; CaC12, 5; glucose, 20; 
tris- (hydroxymethyl)- methylamine; pH adjusted to between 7.7 and 
7.8 with HC1. For drugs and chemicals see Appendix 1. 
General dissection 
A cockroach (male or female) was anaesthetised by cooling, and the 
legs and wings removed. The animal was then pinned, ventral side 
down, through the head and tip of the abdomen to the base of a 
shallow perspex dissecting chamber lined with silicone resin 
(Sylgard, Dow Corning). The body of the cockroach was then covered 
in bathing solution, one of the abdominal segments was raised and 
the exoskeleton ventral and lateral to this was cut. The dorsal 
segments were dissected away at their lateral edges and the tracheal 
tubing and other tissues were removed to expose the internal organs. 
The gut was pinned out to the right to reveal the salivary apparatus 
(Figure 1). The glands were held away from the gut by gripping the 
salivary reservoirs by forceps, and the connective tissue holding 
the glands to the crop and oesophagus was cut, along with some 




































































forward while the uppermost section of the thorax was cut away from 
the head, freeing the ventral nerve cords and exposing the 
mouthparts. The salivary apparatus was then pinned below the head, 
by way of the salivary reservoirs, with care taken not to put any 
strain on the ducts. With the aid of forceps the remaining section 
of the ventral nerve cord was raised from the surface of the common 
salivary duct, the connective tissue holding the nerve cord to the 
duct cut and the nerve cord removed by transection. The salivary 
apparatus was then pinned above the head to allow removal of the 
mouthparts and thus exposure of the hypopharynx. With the salivary 
reservoirs held with a pair of forceps, the apparatus was raised and 
the common duct transected at the hypopharynx. The connective 
tissue holding the common duct in place was then cut and the freed 
salivary structures transferred to bathing solution in the 
experimental chamber. 
Measurement of secretion 
Paired salivary glands were divided to yield two preparations. The 
salivary duct was freed from the adherent reservoir duct, ligated 
near its cut end with braided silk suture (size 0.5 7/0, Sutures 
Ltd). The preparation was mounted in a perspex chamber (House and 
Smith, 1978) lined with silicone resin (Sylgard, Dow Corning). The 
salivary duct was pulled through an orifice in a celluloid barrier 
into an adjacent paraffin pool. The duct was then pierced in front 
of the ligature with a pair of forceps to allow the flow of the 
salivary secretion. The preparation was kept at room temperature 
and superfused at a rate of 18m1 /min. Fluid secreted at the 
ligated end was drawn into a siliconized glass micropipette and 
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transferred to a second paraffin pool where it assumed a spherical 
shape. The volume was calculated from the diameter of the sphere 
which was measured using a microscope with a micrometer eyepiece 
(House and Smith, 1978). Agonists were added to the superfusate 
cumulatively, with the fluid secreted being sampled at 5 min 
intervals. Full equilibration with the agonist was assumed after 
two equivalent responses had been obtained, and the mean rate of 
secretion over this 10 min period was calculated. 
The accuracy of measurement 
The diameter of each droplet could be measured to an accuracy of 
0.25 divisions on the graticule of the eyepiece. Since the 
smallest droplets were about 10 divisions in diameter, the maximum 
error made in estimating the volume of the droplets was 15 %. 
Schild analysis 
The linear relationship between log (dose ratio - 1) and log 
(antagonist concentration) was determined by linear regression in 
the conventional way. If log (dose ratio - 1) = y and 
log (antagonist concentration) = x, then the slope of the line is 
given by C/A where: 
and 
C = n E xy - (Ex) (Ey) 
A = n E x2 - (Ex) 2 
The standard error of the mean for the slope is given by 
V(B - C2/A) / {(n - 2) A) 
where B = n E y2 - (Ey)2 
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RESULTS 
An investigation into the effects of dopamine antagonists 
When added to the superfusate dopamine induced secretion in a 
concentration - related manner. In the presence of the dopamine 
receptor antagonists chlorpromazine (0.1 - 5µM), SCH23390 (10 - 
5µM), haloperidol (10 - 100µM) and metoclopramide (2mM) the 
secretory response to dopamine was inhibited. Provided the 
concentration of chlorpromazine was below 5 AM, SCH23390 below 100µM 
and haloperidol below or equal to 100µM the inhibition was 
surmountable and was reversed by washing with antagonist free 
solution for 30 min. 
Log- concentration - response curves were obtained in antagonist free 
solution, and after a 30 min incubation with an antagonist to a 
range of dopamine concentrations namely, 0.003, 0.001, 0.03, 0.10, 
0.30, 1, 3 and 10µM. At least two experiments were completed with 
the highest concentration of each antagonist used in the present 
study. The responses, r, in the absence and presence of the 
antagonist were fitted to the relationship (Waud and Parker, 1971; 
Barlow and Blake, 1989): 
r = 
M A p 
AP + XP 
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where r is the response in nl /min and A the concentration of 
dopamine. Values for M and p, common to both sets of data, and of 
separate values of X (X1 in the absence and X2 in the presence of 
the antagonist) were estimated by non - linear regression (see 
Appendix II). The values of X1 and X2 correspond to the values for 
the EC50s and the dose ratio was taken as X2 /X1. Figure 2 shows 
the log- concentration - response curve for dopamine in antagonist free 
solution, and in the presence of 5µM chlorpromazine after a 30 min 
exposure. The corresponding data for 50µM SCH23390 and 100µM 
haloperidol are shown in figures 3 and 4 respectively. It is 
evident that for each antagonist the experimental results are 
reasonably well fitted by parallel log- concentration - response curves 
with the same slope and maximum response. This strongly suggests 
that the antagonists behaved in a competitive manner. 
In general, for each antagonist studied, dose ratios were estimated 
using a "three point assay" (Edinburgh Staff, 1968). Three 
concentrations of each antagonist were tested on each preparation. 
The antagonists were added to the superfusate cumulatively, dose 
ratios being estimated after a 30 min incubation with each 
concentration. At least four experiments were completed for each 
antagonist. Table I shows the data from a single experiment in 
which dose ratios were obtained for 10, 20 and 50µM SCH23390. In 
table II, III, IV and V the data obtained in individual experiments 
with chlorpromazine (0.1, 0.5 and 5µM), SCH23390 (10, 20 and 50µM) 
haloperidol (20, 50 and 100µM) and metoclopramide (2mM), 
respectively, are summarized. 
34 
-1.6 O 1.6 
a, LOG10 AGONIST CONCENTRATION 91M) 
FIGURE 2 Inhibitory effect of chlorpromazine on secretion. 
Abcissa : log (dopamine concentration; a). Ordinate : rate of 
secretion in nl /min (r). Open circles show secretory rates in 
antagonist free solution; closed circles show secretory rates in 
the presence of 5µM chlorpromazine after a 30 min exposure. Fitted 
curves are: 
r _ M AP 
AP+ XP 
where M is in nl /min, A is 10a, and represents the agonist 
concentration in pM and p determines the slope of the curve; X 
0.2µM (X1) in the absence of chlorpromazine and 7.4µM (X2) in the 
presence of chlorpromazine; these values represent the 
concentration of agonist which produces 50% of the maximal response. 
The fitting procedure estimated values for M and p (common to the 
data represented by the open and closed circles), and X1 and X2 such 
that the grand sum of the squared vertical deviations of the data 
from the curves was minimized. The value of KD given by these data 
is given by: 
51IM = 0.12µM 
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-1.5 0-5 2.5 
LOG10 AGONIST CONCENTRATION (NM) 
FIGURE 3 Inhibitory effect of SCH23390 on secretion. Abcissa : 
log (dopamine concentration). Ordinate : rate of secretion in 
nl /min. Open circles show secretory rates in antagonist free 
solution; closed circles show secretory rates in the presence of 
50µM SCH23390 after a 30 min exposure. Fitted curves are as in 
figure 1; X - 0.09µM (X1) in the absence of SCH23390 and 2.2µM (X2) 
in the presence of SCH23390. The value of KD given by these data 
was 2.2µM. 
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-2 0 2 
LOG1a AGONIST CONCENTRATION (EM) 
FIGURE 4 Inhibitory effect of haloperidol on secretion. 
Abcissa: log (dopamine concentration). Ordinate rate of 
secretion in nl /min. Open circles show secretory rates in 
antagonist free solution; closed circles show secretory rates in 
the presence of 5µM haloperidol after a 30 min exposure. Fitted 
curves are as in figure 1; X - 0.1µM (X1) in the absence of 
haloperidol and 1.6µM (X2) in the presence of haloperidol. The 













































































































































































































































































































































































































































































































































































































































































Data from "three point assays" of the inhibition by chlorpromazine of the 













OPAMINE CONCENTRATION (pM) 
CHLORPROMAZINE 
5µM 
1 0.01 0.10 0.10 0.40 1.00 
2 0.01 0.05 0.05 0.10 0.50 
3 0.03 0.10 0.30 0.30 1.00 
0.10 0.30 0.30 1.00 10.00 
SECRETION RATE (nl /mín) 
1 3.36 24.54 13.09 23.40 23.50 
2 6.78 27.16 6.70 10.00 18.03 
3 11.22 31.39 21.49 10.56 17.53 
35.92 71.76 46.46 52.38 61.56 
DOSE RATIO 
1 3.47 4.53 11.19 
2 5.03 7.76 20.57 
3 5.42 10.40 22.88 
2.17 6.04 45.58 
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Table III 
Data from "three point assays" of the inhibition by SCH23390 of 











DOPAMINE CONCENTRATION (pM) 
1 0.01 0.10 0.2 0.4 0.80 
2 0.01 0.05 0.05 0.10 0.50 
3 0.01 0.05 0.05 0.10 0.00 
4 0.01 0.05 0.10 0.50 1.00 
ECRETION RATE (nl /min) 
1 2.18 28.28 26.07 20.95 13.27 
2 10.44 36.31 20.73 14.50 13.09 
3 7.55 44.70 13.74 8.75 12.57 
4 6.40 28.76 16.29 27.16 9.20 
DOSE RATIO 
1 2.43 7.63 30.08 
2 2.64 7.77 42.41 
3 3.82 9.49 40.22 
4 4.91 11.22 53.25 
Additional values for dose ratios, estimated from fitted dose 
response curves were used in the Schild plot (figure 6) and in 
the calculation of the mean KD for SCH23390 (see table VI), 
namely: for 10µM SCH23390, 5.31, 25.17, 5.45 and 13.24; for 
20µM SCH23390, 8.92; for 50µM SCH23390, 23.93, 7.67, 23.56. 
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Table IV 
Data from "three point assays" of the inhibition by haloperidol of the 











A I B 
I 
DOPAMINE CONCENTRATION (pM) 
1 0.10 1.00 0.30 1.00 1.00 
2 0.10 0.30 0.30 0.30 1.00 
3 0.10 0.30 0.30 1.00 1.00 
4 0.01 0.10 0.10 0.20 0.30 
SECRETION RATE (nl /mín) 
1 16.9 53.77 21.26 35.95 27.16 
2 22.62 42.04 34.06 21.93 35.38 
3 26.41 43.09 28.76 44.18 29.67 
4 11.32 42.04 27.94 24.81 26.35 
DOSE RATIO 
1 2.28 3.04 5.27 
2 1.57 3.12 4.86 
3 2.57 3.10 8.07 
4 2.88 7.27 9.72 
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Table V 
Data obtained from "three point assays" of the 










DOPAMINE CONCENTRATION (AM) 
1 0.01 0.50 0.50 
2 0.01 0.05 0.10 
3 0.01 0.10 0.10 
4 
SECRETORY RATE (nl /min) 
1 10.79 43.16 17.85 
2 5.06 24.09 5.01 
3 4.29 23.34 6.44 







To test for competitiveness the mean dose ratios for each antagonist 
were subjected to Schild analysis (Arunlakshana and Schild, 1959; 
see below). The slopes obtained from the plot of log (mean dose 
ratio - 1) against log (antagonist concentration) were as follows: 
chlorpromazine, 0.9 ± 0.3; haloperidol, 1.0 ± 0.4; SCH23390 1.1 ± 
0.2. These values appear sufficiently close to unity for the 
antagonists to be said to act in a competitive manner over the 
concentration range studied. Figures 5 - 7 show the corresponding 
plots with the slopes set to unity. 
Determination of KDs from dose ratios 
The equilibrium dissociation constant, KD, was estimated from 
individual dose ratios, DR, from the relationship: 
KD=B/ (DR - 1) 
where B is the antagonist concentration. The geometric mean of the 
KD for each antagonist was calculated according to the relationship 
(Sokal and Rohlf, 1969): 
G.M. = antilog 1/n (E log y) 
where n is the number of values for the KD, Y, and YG.M, is the 
geometric mean. The 95% confidence limits were calculated 
according to the relationship: 
Lower limit = L1 = YG.M. - (t0.05 SY) 
Upper limit = L2 = YG.M. + (t0.05 SY) 
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LOG,o ANTAGONIST CONCENTRATION (M) 
FIGURE 5 "Schild plot" obtained for inhibition by chlorpromazine 
of the secretory response to dopamine. Abcissa: log (antagonist 
concentration). Ordinate: log(dose ratio -l). The line was fitted 
by linear regression with the slope set to 1. Each point 
represents the mean value from at least four experiments. The 


















LOG,o ANTAGONIST CONCENTRATION (M) 
FIGURE 6 "Schild plot" obtained for inhibition by SCH23390 of 
the secretory response to dopamine. Abcissa: log (antagonist 
concentration). Ordinate: log (dose ratio -1). The line was 
fitted by linear regression with the slope set to 1. Each point 
represents the mean value from at least four experiments. The 




LOG10 ANTAGONIST CONCENTRATION (M) 
FIGURE 7 "Schild plot" obtained for inhibition by haloperidol of 
the secretory response to dopamine. Abcissa: log (antagonist 
concentration). Ordinate: log (dose ratio -1). The line was 
fitted by linear regression with the slope set to 1. Each point 
represents the mean value from at least four experiments. The 
intercept on the abcissa indicates a value of 17.5µM for the KD of 
haloperidol. 
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where t0.05 is the significance when P < 0.05. Sy is the standard 
error of the mean: 
Standard deviation = S = IE(y - y)2 /(n -1) 
SEM = Sy = S //ri 
The KDs obtained from individual experiments with chlorpromazine 
(0.5, 1 and 5µM), SCH23390 (10, 20 and 50µM), haloperidol (20, 50 
and 1000M) and metoclopramide (2mM) are shown in table VI, which 
gives values for the geometric mean of the KD for each antagonist 
together with 95% confidence limits. These data give the following 
rank order of potency (KD in parentheses): chlorpromazine (0.12µM) 
> SCH23390 (2.2µM) > haloperidol (17.4µM) > metoclopramide (1.2mM). 
Although there is a considerable scatter between the individual 
values (see figure 8), a clear separation between chlorpromazine, 
SCH23390, haloperidol and metoclopramide is evident. 
In contrast to the antagonists discussed above the selective D2 
receptor antagonists domperidone and ( ±)sulpiride failed to inhibit 
the secretory response to dopamine. 
An investigation into the effects of dopamine receptor agonists 
The dopamine receptor agonists fenoldopam, SKF38393, quinpirole and 
LY163502 (not studied further) all induced secretion from the 
salivary gland. Figure 9 shows the effect of increasing the 
concentration of fenoldopam on the secretory response. One can see 
that secretion was induced in a concentration - related manner. 
Figure 10 compares the log- concentration - response curve obtained to 
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Table V1 Dose ratios estimated by 'three point assay for each of the 
active dopamine antagonists together with the geometric mean KDapp and 
































































































CLZ SCH HAL MET 
ANTAGONIST 
FIGURE 8 Diagram showing the range of values obtained in 
different experiments for the log KD of each antagonist tested 
against the secretory response to dopamine. Ordinate shows the log 
KD (M). CLZ is chlorpromazine; SCH is SCH23390; HAL is 
haloperidol; MET is metoclopramide. 
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50 - 
A B C D 
FIGURE 9 Block diagram showing the concentration- related 
induction of secretion by fenoldopam. Ordinate: rate of secretion 
in nl /min. The height of the columns indicates the secretory 
response: A to 1µM, B to 3µM, C to 10µM, and D 100µM fenoldopam. 
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dopamine (0.003 - 114M) and to fenoldopam (1 - 1000M) in a single 
experiment. Fenoldopam is clearly less potent as an agonist of 
secretion than is dopamine, but produces a parallel log - 
concentration- response curve with an equivalent maximum response. 
Figures 11 and 12 show the corresponding data for SKF38393 and 
quinpirole. It is evident that these two agonists are of lower 
potency than either dopamine or fenoldopam, and neither was able to 
produce the same maximal response as the natural transmitter. The 
threshold concentrations for the agonists was 4.8 ± 1.8µM (n =4) 
for fenoldopam, 41 ± 21 µM (n = 4) for SKF38393 and 132 ± 58 µM for 
quinpirole. On this basis the rank order of potency appeared to be 
dopamine > fenoldopam > SKF38393 > quinpirole. 
As SKF38393 and quinpirole failed to induce the same maximal rate of 
secretion as dopamine, it seemed possible that they were partial 
agonists at the dopamine receptor. In support of this idea, the 
response to dopamine was reduced by high concentrations of these 
agonists. In one of three experiments in which the interaction of 
SKF38393 and dopamine was studied, 100nM dopamine produced a 
secretory response of 62n1 /min, 1mM SKF38393 produced a response of 
40n1 /min and the two together, a response of 40n1 /min. The maximum 
response, produced by 10µM dopamine, was 126n1 /min. In a similar 
experiment, 30nM dopamine produced a response of 42n1 /min, 3mM 
quinpirole, 14n1 /min and the two together, 25n1 /min. The maximum 
rate in this preparation, produced by 1014M dopamine, was 66n1 /min. 
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AGONIST CONCENTRATION (jiM; LOG SCALE) 
FIGURE 10 Comparison of the log- concentration- response curves 
for dopamine and fenoldopam. Abcissa: agonist concentration in AM 
(logarithmic scale). Ordinate: rate of secretion in nl /min. 
Open squares represent the response to dopamine. Closed squares 
represent the response to fenoldopam. These data were obtained 
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AGONIST CONCENTRATION ((M; LOG SCALE) 
FIGURE 11 Comparison of the log- concentration - response curves 
for dopamine and SKF38393. Abcissa: agonist concentration (/LM; 
logarithmic scale). Ordinate: rate of secretion in nl /mín. Open 
squares represent the response to dopamine. Closed squares 
represent the response to SKF38393. These data were obtained from 
a single experiment. 
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.1 1 10 100 1000 10000 
AGONIST CONCENTRATION (pM; LOG SCALE) 
FIGURE 12 Comparison of the log- concentration - response curves 
for dopamine and quinpirole. Abcissa: agonist concentration (pM; 
logarithmic scale). Ordinate: rate of secretion in nl /mín. Open 
squares represent the response to dopamine. Closed squares 
represent the response to quinpirole. These data were obtained 
from a single experiment. 
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Anta:onism of the effects of the dopamine aonists b + SCH23390 
and ( ±)sulpiride Figure 13 shows the log- concentration - response 
curve to fenoldopam in antagonist free solution, and in the presence 
of 10µM ( +)SCH23390 after a 30 min exposure. It is evident that 
the log- concentration - response curve to fenoldopam is shifted to the 
right in the presence of 10µM ( +)SCH23390. The inhibitory effect 
of 10µM ( +)SCH23390 on the responses to SKF38393 and quinpirole was 
investigated by "three point assay ", as shown in figures 14 and 15, 
respectively. The mean value of the KD obtained for ( +)SCH23390 
after a 30 min exposure was 0.82µM (n = 7). This value is 
approximately half that obtained for ( ±)SCH23390 (no longer 
available) against dopamine (2.2µM), as would be expected when 
comparing the action of the racemate and the active enantiomer of an 
antagonist. 
In contrast to ( +)SCH23390, ( ±)sulpiride failed to inhibit the 
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AGONIST CONCENTRATION (uM; LOG SCALE) 
FIGURE 13 Inhibition by SCH23390 of the secretory response to 
fenoldopam. Abcissa: agonist concentration (SM; logarithmic 
scale). Ordinate: secretory rate in nl /mín. Open squares: 
secretion in the absence of antagonist. Closed squares: secretion 
















FIGURE 14 Inhibition by SCH23390 of the secretory response to 
SKF38393. Open columns: rate of secretion in nl /mín induced by 10 
and 100µM SKF38393 in the absence of the antagonist. Filled 
column: the response to 1mM SKF38393 in the presence of 10µM 
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FIGURE 15 Inhibition by SCH23390 of the secretory response to 
quinpirole. Open columns: rate of secretion in nl /min induced by 
200 and 400µM quinpirole in the absence of the antagonist. Filled 
column the response to 1mM quinpirole in the presence of 10µM 
( +)SCH23390 after a 30min exposure. 
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DISCUSSION 
Dopamine- induced secretion from the cockroach salivary gland was 
antagonised by SCH23390, chlorpromazine, haloperidol and 
metoclopramide. These antagonists acted in a concentration - related 
and competitive manner. The rank order of potency was 
chlorpromazine > SCH23390 > haloperidol » metoclopramide. 
Although there was a considerable scatter between the results of 
individual experiments with a particular antagonist, a separation 
between the different antagonists was clear. There was also a 
clear separation between these antagonists and ( ±)sulpiride and 
domperidone which entirely failed to antagonise the response to 
dopamine. 
Comparison with mammalian D1 receptors 
SCH23390 is a selective antagonist of mammalian D1 receptors, while 
( ±)sulpiride, domperidone, metoclopramide and to a lesser extent 
haloperidol show selectivity for the D2 receptor (see Introduction). 
The fact that SCH23390 antagonised the secretory response to 
dopamine, while ( ±)sulpiride and domperidone did not, suggests that 
the receptor mediating secretion is pharmacologically similar to the 
mammalian D1 receptor. At first sight the inhibition of secretion 
by haloperidol and metoclopramide might be thought to be 
inconsistent with such a classification. It should be noted 
however that the concentrations of these compounds required to 
inhibit the secretory response in the present study are also 
inhibitory at the mammalian D1 receptor (Flaim et al, 1985; 
Hilditch and Drew, 1985). 
59 
The suggestion that the dopamine receptors on the cockroach salivary 
gland are similar to the D1 receptor is supported by the studies 
with selective agonists. Thus both D1 and D2 agonists induced 
secretion, the rank order of potency being dopamine > fenoldopam > 
SKF38393 > quinpirole. Furthermore, the response to all agonists 
was inhibited by the selective D1 antagonist ( +)SCH23390, but not 
the selective D2 antagonist ( ±)sulpiride. The rank order of 
potency, dopamine > fenoldopam > SKF38393 is the same as for 
mammalian D1 receptors (Flaim et al, 1985; Hilditch and Drew, 1986; 
Niznik et al, 1988; Ohlstein et al, 1984). In addition the 
finding that SKF38393 has actions consistent with those of a partial 
agonist mirrors the results of 
receptor -mediated relaxation of 
a weak stimulant action of the 
Hilditch and Drew (1985) on the D1 
the rabbit splenic artery. Equally 
selective D2 agonist quinpirole has 
also been observed on mammalian D1 receptors sabserving pancreatic 
secretion in dogs (Horiuchi et al, 1989). As in the cockroach 
salivary gland, the induction of pancreatic secretion by quinpirole 
was antagonised by the D1 antagonist, SCH23390, but not the 
selective D2 antagonist, ( ±)sulpiride. 
Additional support of the D1 classification for the dopamine 
receptor in the cockroach salivary gland, arises from the fact that 
activation of this receptor leads to an increase in cytosolic c -AMP 
levels (Grewe and Kebabion, 1983), and that c -AMP is an intermediate 
in the secretory response (Gray et al, 1984). 
However, a clearly anomalous finding is the low potency of SCH23390 
at the receptor on the cockroach salivary gland, the KDapp being 
perhaps between 2 and 5 orders of magnitude higher than that found 
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in other functional studies on mammalian D1 receptors, where 
SCH23390 has been found to be the most potent antagonist (Hilditch 
and Drew, 1985; Anderson et al, 1985). Not all D1 receptors 
however have an identical pharmacology and there are striking 
differences in the potency of ( ±)sulpiride at D1 receptors in a 
variety of preparations. The selective D1 antagonist SCH23390 
inhibits the effects of dopamine on the endothelium and smooth 
muscle of the rabbit splenic artery (Hilditch and Drew, 1985; 
Ohlstein et al, 1984), rabbit mesenteric vascular bed (Missalle et 
al, 1985; Hilditch and Drew, 1985), rat striatum (Anderson et al, 
1985) and renal cortex (Baldi et al, 1988; Felder et al, 1989). 
In contrast ( ±)sulpiride is only a weak antagonist at D1 receptors 
in the mesenteric vascular bed and fails to antagonise the action of 
dopamine at D1 receptors on the smooth muscle of the rabbit splenic 
artery ( Hilditch and Drew, 1985; Ohlstein et al, 1984; Missalle et 
al, 1985). However, ( +)sulpiride is an antagonist at dopamine D1 
receptors of the rabbit splenic artery ( Ohlstein et al, 1984) and 
( ±)sulpiride inhibits the dopamine- sensitive adenylyl cyclase of the 
rat striatum (Anderson et al, 1985) and renal cortex (Baldi et al, 
1988; Felder et al, 1989). Moreover, the affinity of 
( ±)sulpiride for the receptor in the striatum is much lower than 
that for the receptors on the renal cortex (Anderson et al, 1985; 
Baldi et al, 1988; Felder et al, 1989). The potency of dopamine 
receptor agonists may also prove to be important in the 
subclassification of D1 receptors, as, in contrast to its activity 
in most D1 receptor models fenoldopam was found to be a more potent 
agonist than dopamine of D1 receptors in the rabbit and dog 
mesenteric vascular bed (Hildith and Drew, 1985; Missalle et al, 
1985). It is also interesting to note that investigations of D1 
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receptors in the amygdala have failed to identify a dopamine- 
sensitive adenylyl cyclase (Mailman et al, 1986; Dawson et al, 
1986; Walaas and Greengard, 1984). The D1 receptors described 
above and the receptor on the cockroach salivary gland, at which 
SCH23390 is a relatively weak antagonist, may represent hitherto 
unrecognised subtypes of the D1 dopamine receptor. 
Comparison with other invertebrate dopamine receptors 
Of great importance to the understanding of invertebrate physiology 
and receptor evolution is the comparison of the pharmacology of 
receptors for individual neurotransmitters within a particular 
species and also between different species. The most interesting 
comparison is to be made with the dopamine- sensitive adenylyl 
cyclase system of the locust (L. migratoria) salivary gland, where 
the antagonist rank order of potency and the KD of the individual 
antagonists were almost identical to those obtained for the 
cockroach salivary gland (Lafon -Cazal and Bockaert, 1984). The 
most striking similarity was the low potency of SKF38393 which, as 
in the present investigation, inhibited the response to dopamine 
when the two compounds were applied in combination. Similarities 
also exist between the receptor on the cockroach salivary gland and 
the D1 -like receptor on growth hormone producing cells of the snail 
(Lymnaea stagnalis). Stoof et al (1984) established that SKF38393 
mimicked one of two actions of dopamine on this preparation, while 
SCH23390 inhibited this response to both agonists. In contrast, 
the studies of Orr et al (1987) have identified in the cockroach 
(Periplaneta americana) brain, a dopamine receptor which has a 
pharmacological profile distinct from either the mammalian D1 or D2 
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receptor. This is also true of the dopamine receptor on the 








The data presented in the previous chapter suggests that the 
dopamine receptor mediating the secretory response of the cockroach 
salivary is similar to the mammalian D1 sub -type. House (1973) 
found that, in addition to secretion, dopamine induces a 
hyperpolarization of the salivary gland acinar cells. Subsequent 
studies established that a calcium- dependent potassium conductance 
underlies the hyperpolarization (Ginsborg et al, 1974 and 1980) 
which, unlike secretion, is independent of c -AMP (Gray et al, 1984). 
Due to the fact that c -AMP acts an intermediate in the secretory 
response to dopamine, but not the hyperpolarizing response, it was 
suggested that a different dopamine receptor subserved each event. 
It is therefore of some interest to study the pharmacology of the 
receptor mediating the hyperpolarization. To enable as close a 
comparison of the pharmacology of the two events, the protocol used 
in the present investigation follows closely that of the previous 
study. Thus (i) the rank order of potency was obtained for the 
selective D1 antagonist SCH23390, the selective D2 antagonists 
domperidone, ( ±)sulpiride, haloperidol and metoclopramide and the 
non - selective dopamine antagonist chlorpromazine, (ii) a study was 
made of the ability of two selective D1 agonists, fenoldopam and 
SKF38393, and two selective, D2 agonists LY163502 and quinpirole, to 
induce a hyperpolarization and (iii) the effects of SCH23390 and 
( ±)sulpiride was studied on the responses obtained to the agonists 
used in (ii). 
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METHODS 
The dissection has been described in Chapter III. Paired salivary 
glands and associated ducts were pinned to the base of a perspex 
chamber by way of four troughs filled with silicone resin (Sylgard, 
Dow Coming). The main ducts of the gland were drawn into a suction 
electrode to allow stimulation of the encapsulated nerve. The 
preparation was kept at room temperature (18 -25 °C) and superfused at 
a rate of 5m1 /min. 
Experimental design 
Experimental chamber Figure 16 illustrates the chamber used in 
electrophysiological investigations. It was constructed from a 
circular piece of perspex with a central channel cut in an H shape, 
covering approximately 3/4 of the diameter. At each end of the 
channel corresponding to the 'horizontal bar' of the H at the point 
of the junction with the vertical line, net baffles were placed to 
remove air bubbles from and smooth the flow of the superfusate. In 
the centre of the channel four troughs were positioned in the shape 
of a square whose area approximated that of the preparation. The 
troughs were filled with silicone resin (Sylgard, Dow Corning), 
which allowed the salivary gland to be pinned firmly to the base of 
the dish. At one side of the channel and in line with these 
troughs a holder for the suction electrode (see below) was built 
into the chamber. This was angled at approximately 70° to the 
horizontal in order to direct the suction electrode to the base of 
the channel at the front of the trough over which the common duct of 


































































































upper side of a perspex triangular prism, of about the same size as 
the electrode. When pressed into this channel the suction 
electrode was held firmly in place. 
The suction electrode The suction electrode was made from a 
rigid polythene tube from which a glass tube protruded into the 
bathing solution. The tip of the glass tube was drawn out so that 
its internal diameter was about the same size as that of the common 
salivary duct. A platinum wire within the glass tube was the 
anode, the cathode being a platinum ring on the outer surface which 
was immersed in bathing solution. The common salivary duct, which 
encapsulates the suboesophageal nerve, was drawn into the electrode 
by suction, applied by means of a syringe which ensured that the tip 
of the suction electrode was filled with bathing fluid. Stimuli 
consisted of either a single pulse or short trains of pulses (100V, 
20Hz, 0.5ms pulse width) from a square pulse stimulator (Devices, 
Isolated stimulator, Type 2521). 
Local application of dopamine receptor agonists Agonists were 
applied locally to the acini via ejection, by a pulse of fixed 
pressure (35kPa), from the tip of a broken microelectrode which was 
filled with bathing solution containing the agonist (Picospritzer 
II, General Valve Corporation). 
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Recording of electrical activity of the acinar cells Membrane 
potentials were recorded with glass microelectrodes made on a 
horizontal electrode puller (P -77 Brown- Flaming Micropipette Puller, 
Sutter Instrument Company) from borosilicate glass cappillaries, 
containing an inner filament to aid filling (Clark Electromedical 
Instruments, Cat.No. GC120F -15). These electrodes (20 -40M0 
resistance) were filled with 3M KC1 using a syringe, pulled to a 
fine point under heat to allow its insertion into the tip of the 
microelectrode. The electrodes were connected, via a pre - amplifier 
(Dagan 8900 Patch Clamp, current clamp mode), to a digital audio 
processor (Sony PCM- 701ES) and a video recorder (Sony SL -F30) (see 
Figure 17). From the output of the digital audio processor 
connections were also made to a dual beam oscilloscope (Tektronix 
Inc., Type 565) and a pen recorder to allow the membrane potential 
to be monitored during the experiments. The microelectrodes were 
lowered into position by means of a Leitz micromanipulator and 
placed close to the acinus. The acinar cell was penetrated by 
using the fine control of the manipulator and /or a light tap on the 
air table on which the apparatus rested. The bath electrode 
consisted of AgCl- coated Ag wire which was mounted on the microscope 
stage holding the experimental chamber. The bath electrode was 
connected to earth via a calibrator (see Figure 17). 
Control of stimuli applied to the acinus The stimuli applied to 
the preparation were controlled automatically by means of a Neurolog 
system (Digitimer Research Instruments). The setup allowed 
stimulation of the salivary nerve and local application of agonists 
to occur alternately with a set time interval between each form of 









I, 1 RECORDING ELECTRODE 
FIGURE 17 Diagram of the apparatus used for stimulation and 
recording: A e Neurolog System; B = pen recorder; C = 
oscilloscope; D s digital audio processor; E = video recorder; F 
= calibrator. 
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contains from left to right: (A) first counter unit (Digitimer, 
NL603); (B) first delay -width unit (Digitimer, NL403); (C) pulse 
buffer unit (Digitimer, NL510); (D) period generator unit 
(Digitimer; NL303); (E) second counter unit (Digitimer, NL603); 
(F) third counter unit (Digitimer, NL603); (G) fourth counter unit 
(Digitimer, NL520). The settings for a 90s interval between 
stimuli were as follows:- 
A. First counter: - 
Upper switch to "run "; 
Lower switch to "preset- reset "; 
Counter set to 18; 
Input from (D) the period generator "out" to "in" of the 
counter; 
Input from (F) the third counter "out" to "Gate" of this 
counter. 
B. First delay -width unit: - 
Switch to "Trig + slope "; 
Delay set to 100µs and 0; 
Width set to 500ms 
C. Pulse buffer unit: - 
Amplitude set to 10V; 
Switch to 0 -10V; 
Input from (B) the delay width unit "out" to "in" on this 
unit 
D. Period generator:- 
Switch to "on "; 
Period set to ls; 
Multiplier set to 5 
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E. Second counter: - 
Upper switch to "run" 
Lower switch to "preset- reset" 
Counter set to 36 
Input from (D) the period generator "out" to "in" on this 
unit 
F. Third counter: - 
Upper switch to "run" 
Lower switch to "preset- reset "; 
Counter set to 18; 
Input from (D) the period generator "out" to "in" on this 
unit; 
Input from (E) the second counter "out" to "reset" on this 
unit 
G. Fourth counter: - 
Upper switch to "run "; 
Lower switch to "preset- stop "; 
Counter set to 09; 
Input from (H) the convertor "TTL out No.1" to "in" on 
this unit; 
Input from (E) the second counter "out" to "reset" on this 
unit 
H. Convertor: - 
Input from "pulses out" of the gated pulse generator 
(external unit controlling the square pulse stimulator 
used to stimulate the nerve) to " -Logic in (B)" of this 
unit 
Input from (G) the fourth counter "out" to "TTL in (B)" of 
this unit 
72 
The (D) fourth counter "counter" controls the number of impulses 
applied to the nerve, in this case 09, which is effectively 10 
impulses. 
Two further connections were made. Both of these were to external 
units and allowed the neurolog to trigger the gated pulse generator 
(Devices, Type 2521) of the square pulse stimulator (Devices, 
Isolated stimulator, Type 2533) and the pressure ejection system 
(Picospritzer II, General Valve Corporation): 
1. From (C) pulse buffer "out" to the "External Stimulus" input of 
the Picospritzer unit. 
2. From (H) the convertor " -Logic out (B)" to the "gate pulse" 
input of the Gated Pulse Generator. 
Investigation of the effects of dopamine receptor antagonists on 
responses to nerve stimulation and dopamine 
Nerve stimulation Submaximal responses were obtained using a 
train of 1 -10 impulses, 0.5ms pulse width; 1 -100V, 20Hz. 
Antagonists were added to the superfusate after four consistent 
control responses had been obtained. No quantitative analysis was 
attempted for the effects of the antagonists on nerve stimulation. 
Dopamine Dissociation constants, KDs, for each of the 
antagonists were determined against responses to dopamine applied 
locally by pressure ejection (5 x 10 -7M, 35kPa, 0.003 -5s). When 
applied in this way the absolute concentration of the agonist at the 


































































































































































































































































































































































































evidence however, that the effective concentration of agonist at the 
acinus is proportional to the duration of a pulse of fixed pressure 
(McCaman et al, 1977; Sakai et al, 1979). In accordance with 
this, it was found in the present investigation that over a 
considerable range of pulse durations, the log- duration - response 
curve was linear (figures 19 and 20). The duration of the pressure 
pulse used for agonist application was therefore assumed to be a 
valid measure of the relative concentration of the agonist and used 
in the estimation of dose ratios. In practice dose ratios were 
estimated by "three point assay" (Edinburgh Staff, 1968). Dose 
ratios were estimated independently on separate preparations for 
three concentrations of each antagonist (except metoclopramide, see 
results). The rate of equilibration of the antagonists was 
variable and full equilibration was sometimes not obtained during 
incubations even as long as 1 hour. For this reason, estimates of 
dose ratios were obtained after a fixed, 30 min period of exposure 
to the antagonist. The corresponding value of KD must be regarded 
as apparent rather than absolute. A separate value for KD was 
obtained from each experiment and the geometric mean KD together 
with 95% confidence limits calculated (see results section of 
Chapter III, p.44). 
Investigation of the effects of dopamine receptor agonists 
Estimation of agonist potency Two features of the potency of 
the agonists were measured : the lowest concentration required to 
produce a measurable response (the minimum effective concentration) 
and the equipotent molar ratio of the agonist and dopamine. To 










































































































































































































































































































































10 40 160 640 
PULSE DURATION (ms; LOG SCALE) 
FIGURE 20 A "log- pulse- duration - response curve" to dopamine 
applied locally by pressure ejection (500nM; 35KPa). Abcissa: 
pulse duration in ms (logarithmic scale). Ordinate: amplitude of 
the hyperpolarization in mV. These data are from the experiment 
illustrated in figure 19. The resting potential of this cell was 
-55mV. 
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agonist, tissues were exposed to a low concentration of the agonist 
for 60s. If this did not produce a response, the preparation was 
washed for 10 min, the concentration of agonist doubled and the 
procedure repeated until a measurable response was obtained. If 
the first concentration produced a response which was small in 
amplitude (<10mV) or fragmented in appearance, this concentration 
was taken as the minimum effective concentration, as experience 
showed that half this concentration produced no response. The 
equipotent molar ratio was obtained by dividing the concentration of 
the test agonist required to produce a sub -maximal response (50 -90% 
of the maximum) by the concentration of dopamine producing a 
response of equal amplitude. 
The effect of + SCH23390 and ± sulpiride on the responses to the 
agonists To assess the ability of the D1 antagonist, SCH23390, 
and the D2 antagonist, ( ±)sulpiride, to inhibit the responses to the 
dopamine agonist, the agonist was applied locally by pressure 
ejection (35kPa, 0.003 -5s). The concentration of the agonist in 
the ejection pipette was 1mM. The antagonists were added to the 
superfusate after four consistent responses had been obtained, and 
superfused for 30 min. 
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RESULTS 
As is well known (House, 1973; Ginsborg et al, 1974) stimulation of 
the suboesophageal nerve evokes a stimulus- dependent 
hyperpolarization of the salivary gland acinar cells. When applied 
locally by pressure ejection, dopamine mimicked the effect of nerve 
stimulation in a duration - dependent manner (see Methods). 
The effects of dopamine antagonists 
Chlorpromazine (0.1 -5µM), SCH23390 (10- 50µM), haloperidol (10- 100µM) 
and metoclopramide (1mM) inhibited the response to nerve stimulation 
and dopamine. However, at higher concentrations some of the 
antagonists had non - specific effects. The inhibition of the 
hyperpolarization by chlorpromazine at concentrations > 5µM was 
insurmountable, while SCH23390 destabilised the acinar cell membrane 
at concentrations >_100pM. The effect of these compounds could 
therefore be studied only over a limited range. 
Nerve stimulation Figure 21 illustrates the effect of 
chlorpromazine on the response to nerve stimulation. A shows the 
response to 2 impulses applied to the nerve in antagonist free 
solution. B shows the response to an identical stimulus in the 
presence of 0.5µM chlorpromazine. C shows the effect of increasing 
the number of impulses to 9 still in the presence of chlorpromazine 
after a 30 min exposure. One can see that chlorpromazine inhibited 
the response to nerve stimulation and that increasing the stimulus 
overcame the blockade. Although Bowser -Riley et al (1978) 
established that useful estimates of an antagonist's KD can be 
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obtained against nerve stimulation, no attempt was made to carry out 
a quantitative analysis in the present study. The effects of 
SCH23390, haloperidol and metoclopramide are shown in a 
corresponding way in figures 22, 23 and 24. Chlorpromazine (0.1, 
0.5 and 5µM), SCH23390 (10, 20 and 50µM), haloperidol (10, 20 and 
100pM) and metoclopramide inhibited the hyperpolarization to nerve 
stimulation. The inhibition of the response by chlorpromazine 
(0.1 -5µM) and SCH23390 (10 -50µM) could be surmounted and was 
reversed on washing with antagonist free solution. However, the 
blockade of the hyperpolarization by haloperidol (100pM only) and 
metoclopramide (1mM) was insurmountable, and the inhibitory action 
of haloperidol (10- 100µM) was not reversed after a 30min wash with 
antagonist free solution. In contrast, the inhibition by these 
compounds of the response to dopamine was found to be surmountable 
and was reversed on washing (see below). Thus haloperidol and 
metoclopramide may have an additional pre- synaptic action. 
Of the more selective D2 receptor antagonists, ( ±)sulpiride failed 
to inhibit the response to nerve stimulation, while domperidone (50 
& 100pM) inhibited the response through a pre- synaptic action (see 
Chapter VI). 
Dopamine A more quantitative analysis of the effects of the 
antagonists was undertaken with respect to the hyperpolarization 
produced by dopamine applied locally by pressure ejection (see 
methods). Figure 25 illustrates a typical "three point assay" for 
chlorpromazine. A shows the response to a 150ms pulse of dopamine 
and B the response to a 300ms pulse in antagonist free solution. C 








FIGURE 21 Inhibition by chlorpromazine of the electrical 
response to nerve stimulation (100V; 20Hz). A: the response to 4 
impulses in the absence of the antagonist. B: the response to an 
identical stimulus in the presence of O.5pM chlorpromazine. C: 
the effect of increasing the number of impulses to 9; 
chlorpromazine had been in contact with the preparation for 30min. 
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40mV 
40s 
FIGURE 22 Inhibition by SCH23390 of the electrical response to 
nerve stimulation (100V; 20Hz). A: the response to 2 impulses in 
the absence of the antagonist. B: the response to an identical 
stimulus in the presence of 20µM SCH23390. C: the effect of 
increasing the number of impulses to 32; SCH23390 had been in 
contact with the preparation for 30min. The resting potential was 
-40mV. 
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FIGURE 23 Inhibition by haloperidol of the electrical response 
to nerve stimulation (100V; 20Hz). A: the response to 2 impulses 
in the absence of the antagonist. S: the response to an identical 
stimulus in the presence of 20µM haloperidol. C: the effect of 
increasing the number of impulses to 5; haloperidol had been in 
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FIGURE 24 Inhibition by metoclopramide of the electrical 
response to nerve stimulation (100V; 20Hz). A: the response to 10 
impulses in the absence of the antagonist. B: the response to an 
identical stimulus in the presence of 1mM metoclopramide. C: the 
effect of increasing the number of impulses to 50; metoclopramide 
had been in contact with the preparation for 30min. The resting 
potential was -42mV. 
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0.5µM chlorpromazine to the superfusate. D shows the effect of 
increasing the duration of the dopamine pulse to 700ms in the 
presence of chlorpromazine after a 30min exposure. From B and C 
one can see that the response to dopamine is inhibited by 0.5µM 
chlorpromazine, and that increasing the duration of the dopamine 
pulse to 700ms overcomes the blockade and produces a 
hyperpolarization (D) whose amplitude lies between that of the two 
control responses (A & B). Figures 26, 27 and 28 illustrate in a 
corresponding way the effects of 20µM SCH23390, 20µM haloperidol and 
1mM metoclopramide on the response to dopamine. It is evident that 
all four antagonists inhibited the response to dopamine. In each 
case the blockade could be surmounted by increasing the duration of 
the pulse of dopamine and was reversed on washing with antagonist 
free solution. From experiments such as these dose ratios were 
estimated for chlorpromazine (0.1, 0.5 and 5µM), SCH23390 (10, 20 
and 50µM), haloperidol (10, 20 and 100µM) and metoclopramide (1mM). 
The data obtained are shown in tables VII -X. From the dose ratios 
of individual experiments a separate value of the KD was obtained 
and the geometric mean of the KD with 95% confidence limits 
calculated (as described in the results section of Chapter III). 
These data are summarised in Table XI. The rank order of potency 
for the antagonists was as follows (KD in parentheses): 
chlorpromazine (0.2µM) > SCH23390 (4.1µM) = haloperidol (3.3µM) > 
metoclopramide (265µM). Although there is a considerable scatter 
between the KDs from individual experiments a clear separation was 
evident between chlorpromazine, SCH23390 and haloperidol, and 









FIGURE 25 Antagonism by chlorpromazine of the hyperpolarization 
induced by dopamine applied locally by pressure ejection (500nM; 
3SKPa). A and B show the hyperpolarization to a 150ms and 300ms 
pulse of dopamine, respectively, in the absence of chlorpromazine; 
C shows the inhibition of the response to the larger of these two 
stimuli upon addition of 0.5pM chlorpromazine to the perfusate. D 
illustrates the effect of increasing the duration of the dopamine 
pulse to 700ms. At this point the period of exposure to 










FIGURE 26 Antagonism by SCH23390 of the hyperpolarization 
induced by dopamine applied locally by pressure ejection (500nM; 
35KPa). A and B show the hyperpolarization to a 20ms and 40ms 
pulse of dopamine, respectively, in the absence of SCH23390; C 
shows the inhibition of the response to the larger of these two 
stimuli upon addition of 20µM SCH23390 to the perfusate. D 
illustrates the effect of increasing the duration of the dopamine 
pulse to 80ms. At this point the period of exposure to SCH23390 










FIGURE 27 Antagonism by haloperidol of the hyperpolarization 
induced by dopamine applied locally by pressure ejection (500nM; 
35KPa). A and B show the hyperpolarization to a 50ms and 150ms 
pulse of dopamine, respectively, in the absence of haloperidol; C 
shows the inhibition of the response to the larger of these two 
stimuli upon addition of 20µM haloperidol to the perfusate. D 
illustrates the effect of increasing the duration of the dopamine 
pulse to 300ms. At this point the period of exposure to 









FIGURE 28 Antagonism by metoclopramide of the hyperpolarization 
induced by dopamine applied locally by pressure ejection (500nM; 
35KPa). A and B show the hyperpolarization to a 20ms and 100ms 
pulse of dopamine, respectively, in the absence of metoclopramide; 
C shows the inhibition of the response to the larger of these two 
stimuli upon addition of 20µM metoclopramide to the perfusate. D 
illustrates the effect of increasing the duration of the dopamine 
pulse to 600ms. At this point the period of exposure to 
metoclopramide was 30min. The initial resting potential was -55mV. 
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Table VII 
Data from "three point assays" of the inhibition by chlorpromazine of the 

















DURATION OF DOPAMINE PULSE (ms 
CONTROL 
A I B 
CL2 
5µM 
1 150 300 300 20 100 500 20 30 960 
2 30 90 90 30 50 60 15 30 240 
3 15 30 60 25 50 100 150 300 700 
4 20 40 40 50 150 200 
5 400 800 1000 
HYPERPOLARIZATION (mV) 
1 17 24 17 24 57 55 26 42 30 
2 31 43 33 22 54 28 24 38 39 
3 15 25 19 25 50 54 27 46 35 
4 20 37 27 27 50 40 
5 27 34 26 
DOSE RATIO 
1 2.00 5.51 43.37 
2 2.50 1.82 7.61 
3 3.03 2.08 3.49 
4 1.50 2.15 
5 2.76 
CLZ = chlorpromazine 
90 
Table VIII 
Data from "three point assays" of the inhibition by SCH23390 of the 
















DURATION OF DOPAMINE PULSE (ms 
CONTROL 
A I B 
SCH 
50µM 
1 40 80 120 20 100 2000 10 20 2400 
2 20 40 80 100 200 400 20 80 4800 
3 200 300 400 20 40 100 20 60 1200 
4 20 40 50 80 110 150 15 40 180 
5 100 200 400 5 20 60 
6 25 50 150 
HYPERPOLARIZATION (mV) 
1 14 36 36 22 41 41 42 52 40 
2 26 46 30 36 46 46 27 45 28 
3 43 63 51 22 34 34 21 54 50 
4 22 45 40 26 46 46 24 32 31 
5 33 45 32 42 58 41 
6 11 22 10.5 
DOSE RATIO 
1 1.45 20.00 275.69 
2 3.48 2.35 222.21 
3 1.70 3.30 22.85 
4 1.45 1.59 7.08 
5 4.80 14.27 
6 6.19 
SCH = SCH23390 
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Table IX 
Data from "three point assays" of the inhibition by haloperidol of the 















DURATION OF DOPAMINE PULSE (ms) 
CONTROL 
A I B 
HAL 
100µM 
1 20 50 250 100 200 2000 10 80 80 
2 50 200 200 50 150 300 20 80 3400 
3 80 160 400 10 30 700 30 60 2000 
4 30 60 100 10 30 80 20 60 720 
HYPERPOLARIZATION (mV) 
1 12 44 40 14 31 24 45 59 52 
2 14 22 13 16 40 38 28 46 27 
3 31 36 37 20 30 23 34 60 41 
4 24 34 31 11 30 19 17 30 16.5 
DOSE RATIO 
1 5.61 10.48 5.66 
2 4.76 2.08 39.24 
3 2.20 50.35 55.32 
4 2.10 5.04 46.21 
HAL - haloperidol 
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Table X 
Data from "three point assays" of the 
inhibition by metoclopramide of the 












DURATION OF DOPAMINE PULSE (ms) 
1 4 5 20 
2 120 200 600 
3 20 40 40 
4 20 40 640 
HYPERPOLARIZATION (mV) 
1 24 40 41 
2 28 54 33 
3 40 56 39 







Table X1 Dose ratios estimated by "three point assay" for each of the 
active dopamine antagonists together with the geometric mean KDapp and 
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CLZ SCH HAL MET 
ANTAGONIST 
FIGURE 29 Diagram showing the range of values obtained in 
different experiments for the log KD of each antagonist tested 
against the hyperpolarizing response to dopamine. Ordinate: the 
log KD (M). CLZ is chlorpromazine; SCH is SCH23390; HAL is 
haloperidol; MET is metoclopramide. 
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Unlike the antagonists discussed above, domperidone (1- 100µM) and 
( ±)sulpiride (1- 100µM) failed to inhibit the hyperpolarization to 
dopamine. In fact, the higher concentrations of domperidone (50 & 
100pM) and ( ±)sulpiride (100pM) potentiated the response to 
dopamine; these effects were readily reversed on washing; a more 
detailed analysis of the potentiating effect of these compounds will 
be given in Chapter VI. 
The effects of dopamine receptor agonists 
Potency of agonists All agonists tested hyperpolarized the 
acinar cells. Figure 30 illustrates a typical experiment with 
fenoldopam. A shows the response to the minimum effective 
concentration of fenoldopam (1µM). B shows the response to 50µM 
fenoldopam and C, the response to 100nM dopamine. The effects of 
SKF38393, LY163502 and quinpirole are shown in figures 31, 32 and 33 
respectively. In figure 34 a direct comparison of the potency of 
SKF38393, LY163502 and quinpirole on a single preparation. A shows 
the response to 50µM SKF38393. B shows the hyperpolarization to 
500µM LY163502. C shows the hyperpolarization induced by 1mM 
quinpirole. The minimum effective concentrations and equipotent 
molar ratios obtained from individual experiments for each agonist, 
together with the means ± s.e.m. are shown in table XII. The 
sensitivity of each preparation to agonists varied, as can be seen 
from the range of minimum effective concentrations for each agonist: 
fenoldopam 1 -10µM (n = 4); SKF38393 1 -10µM (n = 4); LY163502 5- 
100µM (n = 4); quinpirole 100pM (n = 4). Thus the relative 
equipotent molar ratios (which allow for variations in sensitivity) 










FIGURE 30 Response to the minimum effective concentration of 
fenoldopam, together with equivalent submaximal responses to 
fenoldopam and dopamine. A shows the hyperpolarization induced by 
lzM fenoldopam (minimum effective concentration). Resting 
potential was -38mV. The hyperpolarizing responses to 50µM 
fenoldopam and 100nM dopamine are illustrated in B and C 
respectively. These two responses were obtained from the same 
cell. The resting potential was -43mV. In each case the agonist 
was added to the superfusate and was in contact with the preparation 








FIGURE 31 Response to the minimum effective concentration of 
SKF38393, together with equivalent submaximal responses to SKF38393 
and dopamine. A shows the hyperpolarization induced by SpM 
SKF38393 (minimum effective concentration). The hyperpolarizing 
responses to 50pM SKF38393 and 100nM dopamine are illustrated in B 
and C respectively. All three responses were obtained from the 
same cell. In each case the agonist was added to the superfusate 
and was in contact with the preparation for lmín. The resting 
potential was -43mV. In A, B and C the arrow marks the beginning 
of the wash. 
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FIGURE 32 Response to the minimum effective concentration of 
quinpirole, together with equivalent submaximal responses to 
quinpirole and dopamine. A shows the hyperpolarization induced by 
100µM quinpirole (minimum effective concentration). The 
hyperpolarizing responses to 1mM quinpirole and 50nM dopamine are 
illustrated in B and C respectively. All three responses were 
obtained from the same cell. In each case the agonist was added to 
the superfusate and was in contact with the preparation for lmin. 
The resting potential was -40mV. In A, B and C the arrow marks the 




FIGURE 33 Response to the minimum effective concentration of 
LY163502, together with equivalent submaximal responses to LY163502 
and dopamine. A shows the hyperpolarization induced by 50µM 
LY163502 (minimum effective concentration). The hyperpolarizing 
responses to 500µM LY163502 and 50nM dopamine are illustrated in B 
and C respectively. All three responses were obtained from the 
same cell. In each case the agonist was added to the superfusate 
and was in contact with the preparation for lmin. The resting 
potential was -40mV. In A, B and C the arrow marks the beginning 





FIGURE 34 Direct comparison of the potency of quinpirole, 
LY163502 and SKF38393. A, B and C show the hyperpolarizing 
responses to 1mM quinpirole, B 500µM LY163502 and 50µM SKF38393 
respectively. These responses were taken from a continuous 
recording from a single cell. Each agonist was added to the 
superfusate and was in contact with the preparation for lmin. The 
resting potential was -38mV. In A, B and C the arrow marks the 































































































































































































































































































































































































































































































































































































































































































































































as follows (relative value in parentheses): dopamine (1) » 
fenoldopam (1,000) > SKF38393 (3,500) > LY163502 (13,750) > 
quinpirole (35,000). 
Effect of .uin.irole on responses to locali alied dopamine 
The response produced by 1mM quinpirole was considerably smaller 
than would be the maximal response to dopamine (- 110mV). As 
quinpirole appeared to have effects on secretion consistent with 
those of a partial agonist, the effect of quinpirole on the 
hyperpolarization to locally applied dopamine was studied. Figure 
35 illustrates the inhibition by quinpirole of the response to 
locally applied dopamine (0.5µM, 35kPa). A and B show control 
responses to dopamine applied by two different durations of pressure 
pulse, 70 and 100ms. On addition of 100µM quinpirole to the 
superfusate a 20mV hyperpolarization was induced, and, as shown in C 
and D, the responses to the 70ms and 100ms pulse of dopamine were 
inhibited. 
The effect of ( ±)sulpiride and ( +)SCH23390 on responses to the 
agonists Although both D1 and D2 receptor agonists 
hyperpolarized the acinar cells, the D1 agonists were more potent. 
This raised the possibility that the D2 agonists were, in fact, 
acting on a D1 receptor. For this reason, a study was made of the 
effects of selective D1 dopamine receptor antagonist, SCH23390 and 
the selective D2 dopamine receptor antagonist, ( ±)sulpiride, on the 
responses to locally applied agonists (1mM, 35kPa). Figure 36 
illustrates the effect of dopamine antagonists on the 
hyperpolarization to fenoldopam. A shows the response to a 300ms 
pulse of fenoldopam in antagonist free solution. B shows the 
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response to an identical stimulus in the presence of 100µM 
( ±)sulpiride after a 30 min exposure. C shows the control response 
of a different cell to a 50ms pulse of fenoldopam. D shows the 
response to an identical stimulus in the presence of 10µM 
( +)SCH23390 after a 30 min incubation. The effects of ( ±)sulpiride 
and ( +)SCH23390 on responses to SKF38893, LY163502 and quinpirole 
are shown in a corresponding way in figures 37, 38 and 39. It is 
evident that the D1 antagonist ( +)SCH23390 inhibited the response to 
all four agonists, while ( ±)sulpiride did not. The inhibition by 
( +)SCH23390 of these responses could be surmounted by increasing the 
duration of the pulse of agonist and was reversed on washing with 





Inhibition of the hyperpolarizing response to 
pressure ejected dopamine (500nM; 
concentration of quinpirole. 
35KPa), by the minimum effective 
A and B show control responses to 




induced by identical stimuli after the addition of 
to the superfusate. The resting potential was 
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FIGURE 36 The effect of ( ±)sulpiride and ( +)SCH23390 on the 
hyperpolarizing response to pressure ejected fenoldopam (1mM; 
35KPa). A shows the response to a 300ms pulse of fenoldopam in 
antagonist free solution. B shows the response to an identical 
stimulus in the presence of 100µM ( ±)sulpiride after a 30min 
exposure. The resting potential was -50mV. C shows a control 
response of a different cell to a 50ms pulse of fenoldopam. D 
shows the response to an identical stimulus in the presence of 
( +)SCH23390 after a 30 min exposure. The resting potential of this 
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FIGURE 37 The effect of ( ±)sulpiride and ( +)SCH23390 on the 
hyperpolarizing response to pressure ejected SKF38393 (1mM; 35KPa). 
A shows the response to a 150ms pulse of SKF38393 in antagonist free 
solution. B shows the response to an identical stimulus in the 
presence of 100µM ( ±)sulpiride after a 30min exposure. C shows the 
response of the same cell after a wash and D shows the response in 
the presence of ( +)SCH23390 after a 30 min exposure. The resting 
potential of this cell was -44mV. 
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FIGURE 38 The effect of ( ±)sulpiride and ( +)SCH23390 on the 
hyperpolarizing response to pressure ejected quinpirole (1mM; 
35KPa). A shows the response to a 100ms pulse of quinpirole in 
antagonist free solution. B shows the response to an identical 
stimulus in the presence of 100µM ( ±)sulpiride after a 30min 
exposure. C shows the response of the same cell after a wash and D 
shows the response in the presence of ( +)SCH23390 after a 30 min 
exposure. The resting potential of this cell was -52mV. 
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FIGURE 39 The effect of (±)sulpiride and ( +)SCH23390 on the 
hyperpolarizing response to pressure ejected LY163502 (1mM; 35KPa). 
-A shows the response to a 170ms pulse of LY163502 in antagonist free 
solution. B shows the response to an identical stimulus in the 
presence of 100µM ( ±)sulpiride after a 30min exposure. C shows the 
response of the same cell after a wash and D shows the response in 
the presence of ( +)SCH23390 after a 30 min exposure. The resting 
potential of this cell was -40mV. 
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DISCUSSION 
Both exogenously applied dopamine and stimulation of the 
suboesophageal nerve hyperpolarize the cockroach salivary gland 
acinar cells (House, 1973; Blackman et al, 1979). Of the 
antagonists studied chlorpromazine, SCH23390, haloperidol and 
metoclopramide inhibited, in descending order of potency, the 
hyperpolarization induced by both dopamine and nerve stimulation. 
In contrast ( ±)sulpiride and domperidone, a highly selective D2 
antagonist, failed to inhibit the response to dopamine or nerve 
stimulation. 
Investigations into the effect of selective dopamine agonists 
established that the selective D1 agonists, fenoldopam and SKF38393, 
and the selective D2 agonists, LY163502 and quinpirole, induced, in 
descending order of potency, a hyperpolarization of the acinar 
cells. The responses to all four agonists were inhibited by 
( +)SCH23390, but not by ( ±)sulpiride. 
The findings of this investigation are in good agreement with those 
of the investigation into the pharmacology of the secretory 
receptors, which is described in Chapter III. From Table XIII it 
is evident that the rank order of potency for both the antagonists 
and agonists is similar for the receptors mediating the secretory 
and electrical responses of the salivary gland to dopamine. 
Moreover, the KDs obtained for each antagonist in these two studies 
are virtually identical, and both the secretory and electrical 
response to the selective agonists were inhibited by the selective 

























































































































































































































































































































































































































































































































































































































It thus seems highly likely that a single receptor, similar to the 
mammalian D1 sub -type, subserves both the electrical and secretory 
response to dopamine. This conclusion contrasts with the view of 
Gray et al (1984), who suggested that a different receptor mediated 
each response. They reported that c -AMP, the levels of which are 
increased on activation of the dopamine receptor (Grewe and 
Kebabian, 1982), acts as an intermediate in the secretory, but not 
the electrical response to dopamine. This result however would be 
consistent with the idea that two second messengers are linked to a 
single receptor, c -AMP mediating the secretory response and the 
other subserving the hyperpolarization. 
The conclusion that a single receptor might mediate independent 
responses is of considerable interest. D1 receptors were 
originally classified as those dopamine receptors which are 
positively coupled to adenylyl cyclase; D2 receptors were classified 
as those which did not influence the activity of this enzyme 
(Kebabian, 1978; Kebabían and Calne, 1979; Spano et al, 1978), 
although subsequent investigations established that many D2 
receptors were actually negatively coupled to adenylyl cyclase 
(Stoof and Kebabian, 1981; De Camilli et al, 1979; Cote et al, 
1982). This classification, together with the idea that it was 
unlikely that a single receptor could be coupled to more than one 
second messenger system, have complicated the current understanding 
of different types of dopamine receptor. This was evident most 
recently in a review by Anderson et al (1990), who cite the finding 
that c -AMP does not always mimic D1- receptor- mediated events and the 
variation in efficacy of D1 agonists between physiological responses 
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and the biochemical response (activation of adenylyl cyclase) of the 
same preparation (Johansen and White, 1987) as evidence for the sub- 
division of D1 receptors. 
The question which remains relates to the nature of the second 
messenger subserving the hyperpolarization. It is highly probable 
that a calcium- dependent potassium conductance underlies the 
hyperpolarization and that both the electrical and secretory 
responses to dopamine rely, at least in part, on the release of 
calcium from intracellular stores (see Ginsborg and House, 1980). 
It is thus possible that an increase in inositol 1,4,5 triphosphate 
(IP3) underlies the response, as IP3 is now well established as a 
second messenger responsible for receptor- activated release of 
calcium from the endoplasmic reticulum (Berridge and Irvine, 1984). 
In support of this idea, D. MacEwen and I have shown that IP3 and 
protein kinase -C are present in the salivary gland, and activation 
of the dopamine receptors translocates protein kinase -C from the 
cytosol to the membrane fraction of the cell, a process which is 
known to require diacyl glycerol, a bi- product of IP3 formation 
(Nishizuka, 1986). In preliminary experiments I have also found 
that NaF potentiates the hyperpolarization induced by dopamine, 
while LiCl inhibits the hyperpolarization to dopamine in a non- 
competitive manner. These results might be explained by the action 
of NaF as a G- protein activator (Freissmuth et al, 1989), and LiC1 
as an antagonist of the phosphoinositide cycle (Avissar et al, 1988; 
Drummond, 1987). Further support of a role for IP3 may be taken 
from recent findings which suggest that D1 receptors in the rat 
striatum and renal cortex are coupled to phospholipase C (Baldi et 
al, 1988; Felder et al, 1988; Mahan et al, 1990). 
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CHAPTER V 
CHARACTERIZATION OF THE DOPAMINE RECEPTORS 
SUBSERVING THE DEPOLARIZATION 
114 
INTRODUCTION 
As has been mentioned previously, the hyperpolarization induced by 
dopamine and nerve stimulation is occasionally followed by a 
depolarization. It has been suggested (Ginsborg and House, 1976) 
that the hyperpolarizing and depolarizing components are mediated by 
two separate receptors. This chapter describes the ability of 
dopamine agonists to evoke a depolarization, and the effect of 
antagonists on the depolarization to dopamine. The methods are as 




Fenoldopam (1 & 50µM), SKF38393 (10 & 50µM), LY163502 (10 & 100µM) 
and quinpirole (0.1 & 1mM) were all found to induce a depolarization 
when superfused for 1 min. These observations were made in at 
least two experiments with each agonist. However, the depolarizing 
component was most clearly seen when the agonists were applied 
locally by pressure ejection, rather than by superfusion. Figure 
40 illustrates examples of responses to the four different agonists 
applied by pressure ejection. A shows the depolarization to a 
200ms pulse of fenoldopam (n = 1). B shows the depolarization to a 
50ms pulse of SKF38393 (n = 3). C shows the depolarization to a 
150ms pulse of LY163502 (n = 2). D shows the depolarization to a 
100ms pulse of quinpirole (n = 3). The simultaneous occurrence of 
the hyperpolarizing and depolarizing components in the response to 
all the agonists tested provides no support for the idea that these 
components are mediated by separate receptors. 
Antagonists 
Chlorpromazine (0.5 & 5µM), SCH23390 (20 & 50µM) and haloperidol 
(10, 20 & 100µM) inhibited the depolarization to dopamine and to 
nerve stimulation. Figure 41 illustrates the action of 
chlorpromazine. In Al the depolarization induced by a 300ms pulse 
of dopamine in the absence of chlorpromazine is shown; A2 shows the 
depolarization to an identical stimulus in the presence of 5µM 







FIGURE 40 The depolarization induced by D1 and D2 dopamine 
receptor agonists. Each agonist was applied locally by pressure 
ejection (1mM; 35KPa). A shows the response to a 200ms pulse of 
fenoldopam, B the depolarization induced by a 70ms pulse of 
SKF38393, C the response to a 100ms pulse of quinpirole and D the 
response to a 150ms pulse of LY163502. The resting potentials of 
the cells represented in A, B, C and D were -65mV, -30mV, -44mV and 
-SOmV_ The level of the resting potential is marked by the broken 
line. In this and all subsequent figures the depolarization is 
upwards. 
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4 impulses applied to the nerve in the absence of chlorpromazine is 
shown; B2 shows the response to an identical stimulus in 5µM 
chlorpromazine after a 20 min exposure. Figures 42 and 43 
illustrate similar experiments for SCH23390 and haloperidol. In 
one experiment 1mM metoclopramide was found to inhibit the 
depolarization to dopamine. The results of 24 experiments with 
these antagonists are summarized in table XIV. It may be seen that 
the range of concentrations and the order of potency are the same 
for the depolarization as those obtained for the inhibition of the 
hyperpolarizing component of the electrical response (see Chapter 
IV). This does not support the idea that two separate receptors 
mediate the two components and it may be tentatively concluded that 
the depolarization is mediated by the same D1 receptor type as is 
responsible for the hyperpolarization. This conclusion is 
supported by the absence of an inhibitory effect on the 
depolarization of 100µM ( ±)sulpiride, a selective D2 antagonist, 
which is also ineffective against the hyperpolarization. However, 
the results obtained with a second D2 antagonist, namely 
domperidone, were in apparent conflict with this idea. The action 
of domperidone is illustrated in figure 44. Control responses to 
nerve stimulation are shown in Al and A3. In A2 it can be seen 
that the depolarization was abolished by 50µM domperidone. The 
small degree of inhibition of the hyperpolarization was due to a 
pre- synaptic effect since domperidone potentiates rather than 
inhibits the hyperpolarizing effect of dopamine; this will be 
discussed in greater detail in Chapter VI. Figure 44B shows a 
further distinction between the inhibitory action of domperidone and 
the antagonists discussed previously. A control response to nerve 











FIGURE 41 The inhibition by chlorpromazine of the depolarization 
to pressure ejected dopamine (500nM; 35KPa), and to nerve 
stimulation (100V; 20Hz). Al: depolarization induced by a 300ms 
pulse of dopamine in the absence of chlorpromazine. A2: the 
response to an identical stimulus in the presence of 5µM 
chlorpromazine after a 5min exposure. BI: the response of the 
same cell to 4 impulses applied to the nerve in the absence of 
chlorpromazine. B2: the depolarization induced by an identical 
stimulus in the presence of 5µM chlorpromazine after a 20min 
exposure. The resting potential was -40mV. In A and B the level 











FIGURE 42 The inhibition by SCH23390 of the depolarization to 
pressure ejected dopamine (500nM; 35KPa), and to nerve stimulation 
(100V; 20Hz). Al: depolarization induced by a 200ms pulse of 
dopamine in the absence of SCH23390. A2: response to an identical 
stimulus in the presence of 20µM SCH23390 after a 10min exposure. 
The resting potential was -40mV. Bl: the response of a different 
cell to 4 stimuli applied to the nerve in the absence of SCH23390. 
B2: the depolarization induced by an identical stimulus in the 
presence of 20µM SCH23390 after a 20min exposure. Resting 
potential was -30mV. In A and B the level of the resting potential 











FIGURE 43 The inhibition by haloperidol of the depolarization 
to pressure ejected dopamine (500nM; 35KPa), and to nerve 
stimulation (100V; 20Hz). Al: depolarization induced by a 90ms 
pulse of dopamine in the absence of haloperidol. A2: the response 
to an identical stimulus in the presence of 100µM haloperidol after 
a 10min exposure. The resting potential was -50mV. B1: the 
response of a different cell to 2 impulses applied to the nerve in 
the absence of haloperidol. B2: the depolarization induced by an 
identical stimulus in the presence of 100µM haloperidol after a 
25min exposure. The resting potential was -42mV. In A and B the 
level of the resting potential is marked by the broken line. 
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Table XIV 
The effects of antagonists on the depolarization to dopamine and nerve stimulation. 
ANTAGONIST CONCENTRATION MEAN DEPOLARIZATION REVERSED 
(µM) (mV) SURMOUNTED ON WASHING 
CONTROL TEST 
5 5 
0.5 3 1 YES YES 
2.5 0 
CLZ 
3 0 YES YES 




20 6 2 YES 
4 2 
SCH 2 0 
5 0 YES NO 
50 3.5 1 YES YES 
3.25 0 
3 1 NO 
10 2.3 2.3 
6.5 0 YES 
2.5 0 YES NO 
HAL 20 2.5 0 YES NO 
2 0 NO NO 
2.5 0 NO 
100 7.7 0 NO 
3.5 0 NO 
MET 1000 3 0 YES YES 
CLZ = chlorpromazine; SCH = SCH23390; HAL = Haloperidol; MET = Metoclopramide 
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to an identical stimulus fifteen minutes after the addition of 50µM 
domperidone to the superfusate. The depolarization has been 
abolished whilst the hyperpolarization has been potentiated. After 
a further fifteen minutes (B3) the hyperpolarization was also 
inhibited. A similar result was obtained in one other experiment. 
In another experiment, 100µM domperidone was found to inhibit the 
depolarization in response to pressure ejected dopamine whilst 














FIGURE 44 The inhibition by domperidone of the depolarization 
induced by nerve stimulation. Al shows the hyperpolarization and 
the subsequent depolarization induced by 10 impulses applied to the 
nerve (100V; 20Hz) in the absence of domperidone. The inset ( *) 
shows the depolarization at a higher gain, with the level of the 
resting potential marked by the broken line ( A2 shows the 
response to an identical stimulus in the presence of 50µM 
domperidone (20min exposure). A3 shows the response after washing. 
The resting potential was -38mV. Section B, from a different cell, 
illustrates the more rapid time course for the inhibition of the 
depolarization than of the hyperpolarization. Bl shows the 
response to 10 impulses applied to the nerve in the absence of 
domperidone. B2 shows the response to an identical stimulus after 
a 15min exposure to 50µM domperidone. The increased duration of 
the hyperpolarization is increased and the depolarization inhibited. 
B3 shows the response after a futher 15min exposure on. The level 
of the resting potential is marked by the broken line, and was 
-50mV. 124 
DISCUSSION 
In Chapter IV it was established that the hyperpolarization to 
dopamine is mediated by a receptor similar to the D1 sub -type found 
in mammalian systems. In the work described in this chapter the 
selective D2 antagonist domperidone, which is not an antagonist of 
the hyperpolarization, was found to inhibit the depolarizing 
component of the response. This might suggest that different 
receptors subserve the two components of the electrical response, 
thus supporting the view of House and Ginsborg (1976) who found that 
low concentrations of the non - selective dopamine antagonist 
a- flupenthixol inhibited the hyperpolarization without affecting the 
depolarization, an action which is shared by ergometrine (Bowser - 
Riley et al, 1978). This hypothesis becomes more attractive when 
one considers that prolonged exposure to dopamine can lead to a 
reduction in the hyperpolarization to nerve stimulation, without 
inhibiting the depolarization (Ginsborg and House, 1976). However, 
it is clear that if a second receptor is involved it is certainly 
not a classical D1 or D2 sub -type because, as has been shown, a 
selective D1 antagonist inhibited the depolarization to dopamine, 
whilst another selective D2 antagonist did not. Thus the "twin - 
receptor" hypothesis implies the existence of a hitherto 
unrecognized dopamine receptor whose pharmacology included 
activation by all dopamine agonists so far tested, inhibition by the 
D2 antagonist domperidone and by the D1 antagonist SCH23390, but not 
by the D2 antagonist ( ±)sulpiride or by a- flupenthixol. Two other 
sets of results make the "twin- receptor" theory unattractive. 
First, the finding that both the selective D1 agonists, SKF38393 and 
fenoldopam, and the selective D2 agonists, quinpirole and LY163502, 
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induce a hyperpolarization and a depolarization. Secondly, 
chlorpromazine, SCH23390, haloperidol and metoclopramide inhibit the 
depolarization over the same range of concentrations in which they 
inhibit the hyperpolarization. These results taken by themselves 
strongly suggest that a single receptor mediates both components of 
the electrical response. The action of domperidone and a- 
flupenthixol would then be attributed to effects, not on the 
receptor, but on the processes following receptor activation. 
126 
CHAPTER VI 
AN INVESTIGATION INTO THE EFFECTS OF DOMPERIDONE ON 
THE HYPERPOLARIZATION TO DOPAMINE AND NERVE STIMULATION 
127 
INTRODUCTION 
As the selectivity of dopamine receptor ligands is not absolute, it 
was not surprising to find that as in the mammal the selective D2 
antagonists, haloperidol (Iversen, 1975; Snyder et a1, 1975) and 
metoclopramide (Hope et al, 1978; Munemura et al, 1980; Seeman et 
al, 1987) were, in sufficiently high concentrations, effective in 
blocking the responses to dopamine (see Chapters III -V). However 
domperidone and ( ±)sulpiride, which are also selective D2 
antagonists (Laduron and Leyson, 1979; Jenner and Marsden, 1981), 
were found to potentiate rather than inhibit the hyperpolarization 
to dopamine. In an attempt to clarify the nature of the 
potentiation, the effects of domperidone have also been studied on 
the electrical responses to nerve stimulation and to 5 -HT, an 
agonist that acts on distinct receptors from dopamine in this 
preparation (Bowser -Riley et al, 1978). The results suggest that 
the potentiation is due to a post- synaptic action independent of any 
dopamine receptor. The methods are as described in Chapter IV. 
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RESULTS 
The effects of domperidone (1- 100µM) and ( ±)sulpiride (1- 100µM) on 
the electrical response of the salivary gland were studied. 
Addition of 1 (n =4) and 10µM (n =4) domperidone and lµM ( ±)sulpiride 
(n =4) to the superfusate had no effect on the hyperpolarization to 
either nerve stimulation or dopamine. However, 50 (n =3) and 100µM 
(n =4) domperidone and 100µM ( ±)sulpiride (n =3) potentiated the 
hyperpolarization induced by dopamine. Figure 45 illustrates the 
effects of these two compounds after a 30min exposure. Al shows 
the response to a 50ms pulse of dopamine in antagonist free 
solution. A2 shows the response to an identical stimulus in the 
presence of 100µM domperidone and, A3 the response after a 30min 
wash in drug free solution. The effect of ( ±)sulpiride is 
illustrated in a corresponding way in parts Bl, B2 and B3. One can 
see that both an increase in the amplitude and the duration of the 
responses to dopamine resulted from the presence of domperidone or 
( ±)sulpiride, and that the potentiation decreased on washing. It 
is also evident that the potentiation obtained in the presence of 
( ±)sulpiride was much weaker than that obtained in the presence of 
domperidone. Due to this fact, the effects of ( ±)sulpiride were 
not studied further. Figure 46 illustrates the effects of 100µM 
domperidone on the response to dopamine and to nerve stimulation. 
The upper trace (A) shows control responses to two pulses of 
dopamine (DA7 & DA10) together with a response to nerve stimulation 
(NS). The lower trace (B) shows the corresponding responses in the 
presence of domperidone. It is evident that both the amplitude and 
duration of the responses to dopamine have been increased, whereas 
the response to nerve stimulation has been reduced. From this one 
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FIGURE 45 The potentiation by domperidone and by ( ±)sulpiride 
of the electrical response of the acinar cells to pressure ejected 
dopamine (500nM; 35KPa). Al shows the hyperpolarization induced by 
a 50ms pulse of dopamine in the absence of domperidone. A2 shows 
the response to an identical stimulus in the presence of 100íM 
domperidone after a 30min exposure, and A3 the response after a 
wash. The resting potential was -30mV. B1 shows the control 
response of a different cell to a 150ms pulse of dopamine. B2 
shows the response to an identical stimulus in the presence of 100µM 
( ±)sulpiride after a 30min exposure. B3 shows the response after 











FIGURE 46 The effect of domperidone on responses of a single 
cell to dopamine and to nerve stimulation. A: two succesive 
responses to dopamine applied locally by pressure ejection (1pM; 
35KPa) with a duration of 7ms (DA7) and 10ms (DA10), followed by a 
response to a train of 10 stimuli (100V; 20Hz) applied to the nerve 
at the point marked by the arrow (NS). B: responses of the same 
cell to stimuli identical to those in A in the presence of 100pM 
domperidone. The period of exposure was 30min. The resting 
potential was -36mV. 
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might be tempted to conclude that the transmitter at this synapse 
was not, in fact, dopamine. However, the inhibition of the 
response to nerve stimulation resulted from a secondary action (see 
below). The potentiation of the dopamine- induced hyperpolarization 
was maximal at 50µM domperidone, and in general, as mentioned above, 
was manifest as both an increase in the duration and the amplitude 
of the hyperpolarization. The increase in duration was the 
dominant effect, the duration being approximately doubled in six out 
of seven experiments (see table XV). 
At a concentration of 50µM, domperidone was found to potentiate the 
hyperpolarization induced by 5 -HT (n =2). This is illustrated in 
figure 47 from which it may also be seen that the potentiating 
effects of domperidone on the responses to both dopamine and 5 -HT 
are reversed on washing. Al shows a response to locally applied 
dopamine in the absence, and A2 in the presence of 50µM domperidone; 
A3 shows the response after a 30min wash. The corresponding 
responses to 5 -HT are illustrated in parts B1, B2 and B3. 
As mentioned above, the action of domperidone on the response to 
nerve stimulation was more complex than that on the responses to 
applied agonists. As illustrated in figure 48, the decline in the 
response was preceded by a phase of potentiation. Figure 48A shows 
a control response to nerve stimulation, parts B and C show the 
response after exposure to 50µM domperidone for 15min and 30min, 
respectively. Similar results were obtained in two other 
experiments. The reduction in the response to nerve stimulation 
was concentration -dependent, and at a concentration of 100µM 
domperidone abolished the response in two out of four cells. In 
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Table XV 




DOPAMINE- INDUCED HYPERPOLARISATION 
AMPLITUDE (mV) DURATION (s) 
CONTROL TEST OF 
CONTROL 
CONTROL TEST OF 
CONTROL 
50 42 57.5 136 10 23.5 233 
49.3 36.5 74 14.4 38.2 265 
23.3 38.3 164 21.8 22.2 102 
100 34 43 126 8.1 19.6 242 
37 45 122 7.2 20.7 288 
23 24 104 4.8 13.2 275 
26 24 92 7.2 15.0 208 










FIGURE 47 Potentiation by domperidone of the hyperpolarization 
induced by pressure ejection of dopamine (A; 1jM; 35KPa) and 5 -HT 
(B; 10AM; 35KPa). Al: response to a 40ms pulse of dopamine in the 
absence of domperidone. A2: the response of the same cell to an 
identical stimulus in the presence of 50µM domperidone. A3: after 
a 30min wash. The resting potential was -36mV. Bl shows a 
control response of a different cell to a 100ms pulse of 5 -HT. B2 
shows the response to an identical stimulus in the presence of 50ÁM 
domperidone and B3 shows the response after a 10min wash. The 
resting potential was -52mV. In A and in B the period of exposure 
to domperidone was 10min. 134 
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FIGURE 48 The initial potentiation and later inhibition by 
domperidone of the hyperpolarization to nerve stimulation. A shows 
the response to 10 stimuli applied to the nerve (100V; 20Hz) in the 
absence of domperidone. The responses to identical stimuli after a 
15min exposure and a 30min exposure to 50AM domperidone are shown in 
B and C respectively. A, B and C were obtained from the same cell. 
The resting potential was -50mV. 
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the cells where the hyperpolarization was reduced but not abolished, 
the increased duration of the response relative to control was still 
apparent. Following abolition of the response to nerve 
stimulation, an increase in the number of stimuli in the train 
failed to overcome the blockade. The inhibition of the 
hyperpolarization to nerve stimulation was evidently due to a pre - 
synaptic action, since prolonged incubations with domperidone did 




Domperidone potentiated the hyperpolarization induced by locally 
applied dopamine and by locally applied 5 -HT. It also initially 
potentiated the hyperpolarization produced by nerve stimulation. 
One explanation for the potentiation might be that the responses to 
dopamine and 5 -HT are normally limited by some reuptake process and 
that this is antagonised by domperidone. Against this argument is 
the finding that domperidone has no effect on the secretory response 
of the salivary gland to dopamine (see Chapter III). Alternatively 
domperidone might be acting post - synaptically to amplify the 
consequence of receptor activation: Since as shown by Bowser -Riley 
et al (1978), the receptors for dopamine and 5 -HT in this 
preparation are distinct, post- synaptic potentiation of the response 
to both agonists is most easily explained by supposing that 
domperidone acts on some process occurring after receptor 
activation. Although domperidone has not, as far as I am aware, 
been shown to have any effect on possible intermediates between 
receptor activation and response, other dopamine antagonists have 
been shown to inhibit a number of these including protein kinase -C- 
(Petty, 1989), phospholipase A2- (Kahle et al, 1989) and calmodulin- 
dependent processes (Norman and Staehelin, 1982). It seems likely 
that the inhibition of calmodulin may be involved as the 
potentiating effect was common to ( ±)sulpiride, which is known to 
inhibit calmodulin (Norman and Staehelin, 1982). However a firm 
conclusion as to the mechanism of action of domperidone would 
require more direct biochemical assays. 
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CHAPTER VII 
AN INVESTIGATION INTO THE ROLE OF CALMODULIN 
IN STIMULUS- SECRETION COUPLING 
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INTRODUCTION 
A role for calcium in the mediation of cellular processes was first 
proposed by Ringer (1883). However the general view of calcium as 
an intracellular messenger remained unfocused until the discovery of 
calmodulin (Cheung, 1970; Cheung et al, 1975). Calmodulins are 
calcium- binding proteins which, on activation by calcium, interact 
with a variety of target proteins to regulate a number of cellular 
events. 
The structure of calmodulins 
Over 160 structurally related calcium -binding proteins have been 
identified. These have now been grouped into ten sub - families and 
ten unrelated single proteins (for review see Persechini et al, 
1989). Calmodulins are proteins of low relative molecular mass (16 
KDa), comprising a single polypeptide chain of 148 amino acid 
residues. They are unique in that they are present in all 
eukaryotes studied to date (Klee and Vanamen, 1982; Waisman et al, 
1975 & 1977; Yamanaka and Kelly, 1981). The amino acid sequence 
of calmodulins is well conserved throughout evolution (Chafouleas et 
al, 1979) and many invertebrate calmodulins differ from that 
isolated from bovine brain in only 5 to 7 amino acid residues (Klee 
and Vanaman, 1982). Calmodulins are members of the family of 'EF- 
hand homolog' calcium- binding proteins (Persechini et al, 1989). 
The amino acid chain is arranged in the form of a dumbell, with two 
hemispheres positioned at either end of a long central helix. Each 
hemispheric portion of the molecule contains two EF- hands, in which 
the structure is orientated in the form of a helix loop helix. The 
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loop between the helices of the EF -hand represents the calcium - 
binding region of the molecule. Thus calmodulins bind a maximum of 
four calcium molecules, two within each hemisphere (Kretsinger and 
Barry, 1975). Nuclear magnetic resonance spectroscopy has shown 
that conformational changes occur in the EF -hand portion of the 
molecule during the process of calcium- binding (Ikura et al, 1983; 
Krebs and Carafoli, 1982; Iida and Porter, 1986). These changes 
result in an increase in affinity of the vacant calcium- binding 
sites. Calcium - dependent changes in the conformation of 
calmodulins also occur in the backbone connecting the two 
hemispheres. This alteration is complete after the binding of two 
calcium ions (Xu et al, 1983); however the changes in the 
orientation of the amino acids directly involved in the binding of 
calcium are not complete until all four sites are occupied (Seaton 
et al, 1983). It is generally accepted that the conformational 
changes around the calcium- binding sites expose hydrophobic surfaces 
in the hemispheric lobes of calmodulin, with which many target 
proteins interact (Manalan and Klee, 1984; Means and Klee, 1988). 
Many subcellular proteins have been recognized as calmodulin- binding 
proteins, of which a number have been identified as calcium - 
calmodulin regulated enzymes. Several of these proteins have been 
implicated in the control of secretion and their role will now be 
discussed. 
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Subcellular distribution of calmodulin and calmodulin- binding 
proteins 
In rat submandibular glands (Singh et al, 1989) calmodulin is found 
predominantly in the cytosolic fraction of the cell. Less than 1% 
of the total calmodulin content of the rat submandibular acinar 
cells is found in the fraction associated with the mitochondria, 
golgi bodies, endoplasmic reticulum and plasma membranes. However, 
after activation by calcium, calmodulin is found predominantly in 
the particulate fractions (Singh et al, 1989). The reduction of 
calmodulin in the cytosolic fraction appears to reflect the binding 
of calmodulin, on activation of the cell, to target proteins in the 
mitochondria, golgi bodies, endoplasmic reticulum, plasma membrane 
and nuclei in addition to the cytosol (Singh et al, 1989). The 
wide distribution of calmodulin- binding proteins suggests that 
calmodulin may regulate many cellular functions. These include 
secretion, muscle contraction, cell motility, cell growth and gene 
expression (for review see: Klee and Vannaman, 1982; Persechini et 
al, 1989; Rasmussen and Means, 1989). 
Calmodulin and secretion 
Calmodulin has been reported to be responsible, at least in part, 
for the control of calcium- dependent secretion from the rat 
pituitary gland (Das et al, 1989; Schettini et al, 1984, 1985, 
1987; Kile and Amos, 1988), bovine adrenal chromaffin cells 
(Burgoyne et al, 1982; Kenigsberg and Trifaro, 1985), rat and 
rabbit gastric mucosa (Black et al, 1989; Seidler and Sewing, 
1989), rat intestine (Fedorak et al, 1989), rat hypothalamic cells 
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(Lewis et al, 1987), rat peritoneal mast cells (Izushi and Tasaka, 
1989), rat submandibular and parotid salivary glands (Singh et al, 
1989; Tojyo et al, 1989) and sea urchin eggs (Steinhardt and 
Alderton, 1982). In all these cases the secretory response was 
inhibited by prior incubation with calmodulin antagonists, or anti - 
calmodulin antibodies. In their study on the rat parotid salivary 
gland Tojyo et al (1989) found that both isoprenaline- and dibutyryl 
c -AMP- stimulated secretion was inhibited by the calmodulin 
antagonist W7 and the inhibition was reversed by exogenous 
calmodulin. In addition electron micrographic studies established 
that in the presence of W7, agonist- activated cells lost microvilli 
from their luminal surface, retained the majority of secretory 
granules within the cytoplasm and retained the discharged secretory 
material within the lumen of the cell. These effects were not 
mimicked by W5, a close analogue of W7 which possessed only limited 
anti - calmodulin activity. These findings suggest that calmodulin 
may be of importance in the regulation of several aspects of 
calcium- dependent secretion, including cytoskeletal reorganization, 
aggregation of secretory granules and fusion of the secretory 
granules with the plasma membrane. In support of this idea, a 
structurally different calmodulin antagonist, trifluoperazine, 
mimics the effect of W7 on the parotid cells (Tojyo et al, 1989) and 
has been shown to inhibit the formation of secretory vacuoles in the 
adrenal chromaffin cell plasma membrane and the fusion of secretory 
granules with the plasma membrane (Burgoyne et al, 1982). 
Furthermore calmodulin- binding proteins and substrates for 
calmodulin- dependent enzymes have been identified on secretory 
granules and cytoskeletal structures of a number of cell types (see 
Burgoyne and Geisow, 1981; Howe et al, 1983; Geisow and Burgoyne, 
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1987; Fournier and Trifaro, 1988; Parsons and Creutz, 1986; 
Harper, 1988). 
Calmodulin antagonists 
Two of the most potent and selective calmodulin antagonists 
presently available are W7 and calmidazolium. Calmidazolium is 
particularly useful as, unlike the neuroleptic calmodulin 
antagonists, it appears to be free of any activity at cell surface 
receptors at concentrations which inhibit calmodulin (Gietzen et al, 
1981). The structure of these compounds conforms to the classical 
model proposed by Weiss et al (1982): this consists of a bulky 
hydrophobic region, formed by two aromatic rings, which allows 
interaction with the non -polar regions within the hemispheric lobes 
of calmodulins, and a positively charged group, essentially a basic 
nitrogen atom, not less than three carbon atoms from the hydrophobic 
rings. Of the two compounds W7 has been most extensively studied. 
Both high and low affinity binding sites for W7 have been identified 
within calmodulin (Hidaka et al, 1981). The low affinity sites are 
more numerous and are thought to be of little importance to the 
activity of the antagonist. Three high affinity sites have been 
located, all of which are centered around the hydrophobic clefts 
exposed on calcium- binding to the hemispheric lobes ( Hídaka et al, 
1981; Tanaka et al, 1982 & 1983). It is now accepted that the 
inhibition of calmodulin- dependent events by these antagonists 
results from competition with calmodulins target proteins for these 
binding sites (Ovadi, 1988). In -vitro biochemical assays have 
established that the IC50 for inhibition of calmodulin- dependent 
activation of a variety of enzymes by W7 and calmidazolium lies 
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within the range 0.01 -10µM and 25 -100µM respectively (Asano, 1989; 
Van Belle, 1984; Brumley and Wallace, 1989; Hidaka et al, 1981; 
Tanaka et al, 1982; Gietzen et al, 1981). Although both W7 and 
calmidazolium have been shown also to inhibit the activity of 
protein kinase -C and calpain I, the IC50 values are between 5 and 
600 fold higher than those quoted for calmodulin- dependent enzyme 
activities (Brumley and Wallace, 1989). Except for the inhibition 
of protein kinase -C and calpain I, all actions common to both W7 and 
calmidazolium are, at least at present, considered to be specific to 
calmodulin (for review see Ovadi, 1989). 
The aim of the present investigation is to study the involvement of 
calmodulin in the responses of the cockroach salivary gland to 




The addition of W7 to the solution bathing the gland caused 
submaximal secretion. The results of two experiments are given in 
Table XVI. It can be seen that increases in the concentration of 
W7 up to 10µM caused increased rates of secretion but a further 
increase in concentration caused a reduced rate of secretion. 
Figure 49 compares the responses over a range of concentrations to 
W7 and dopamine from the same preparations. The maximum rate of 
secretion induced by W7 was less than 50% of the maximum response to 
dopamine. The period required for full equilibration with W7 
varied within the range 5 - 25 min. Figure 50 shows the response 
to (A) 0.1µM and (B) 0.3µM dopamine; C shows the secretory response 
to 100µM W7 alone, D, the response to 100µM W7 and 0.3µM dopamine in 
combination and, E, the effect of 3µM dopamine with W7 still 
present. It can be seen that W7 inhibited the secretory response 
to dopamine. This inhibition was not overcome by an increase in 
the concentration of dopamine even to a level of 3µM, but was 
reversed after washing with W7 free solution. A similar experiment 
in which the effect of calmidazolium was studied is illustrated in 
Figure 51. Three additional experiments were performed for 
calmidazolium and for W7. It might be supposed that W7 and 
calmidazolium are partial agonists of the dopamine receptor, however 
to my knowledge neither compound has been shown to interact with 
cell surface receptors (see also Gietzen et al, 1981). 
145 
Table XVI 




DIAMETER VOLUME TIME RATE 
(DIV) (nl) (min) nl /min 
E X P E R I M E N T 
1 2 1 2 1 2 1 2 
1.0 0 0 0 0 5 5 0 0 
3.0 9.5 16.0 7.54 33.5 5 5 1.5 6.7 
10.0 23.0 25.0 99.5 127.83 5 5 19.9 25.5 
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Comparison of the log- concentration - response curves 
for dopamine and W7. Abcissa: Secretagogue concentration (µM; 
logarithmic scale). Ordinate: rate of secretion in nl /mín. Open 
squares represent the response to dopamine. Closed squares 










A B C D E 
FIGURE 50 Block diagram illustrating the inhibition by W7 of 
the secretory response to dopamine. Ordinate: rate of secretion 
in nl /min. The columns represent the secretory responses to A, 
0.1µM and B, 0.3µM dopamine in the absence of W7. C: the 
secretory response to 100µM W7. D: the response to 100µM W7 in 
combination with 0.3µM dopamine. E: the response to 100µM W7 in 




A B C D E 
FIGURE 51 Block diagram illustrating the inhibition by 
calmidazolium of the secretory response to dopamine. Ordinate: 
rate of secretion in nl /min. The columns represent the secretory 
responses to A, 0.1µM and B, 0.3µM dopamine in the absence of 
calmidazolium. C: the secretory response to 10µM calmidazolium. 
D: the response to 10µM calmidazolium in combination with 0.3µM 
dopamine. E: the response to 10µM calmidazolium in combination 
with 3µM dopamine. 
149 
Electrophysiology 
The calmodulin antagonists were found to potentiate the 
hyperpolarization to dopamine. Figure 52A shows the response to 
pressure ejected dopamine (500nM, 35kPa) (i) in the absence and (ii) 
in the presence of 0.1µM W7. One can see that the 
hyperpolarizations to dopamine increased in amplitude and duration 
with W7 present. Similar results were obtained in two additional 
experiments. In part B of this figure the potentiation of the 
response by 5µM calmidazolium is illustrated in a corresponding way. 
Similar results were obtained in three other experiments. The 
concentration of calmidazolium required to cause potentiation was 50 
times greater than that of W7. This may reflect the slower entry 
of calmidazolium into the cell, as it has a much higher affinity for 
calmodulin than does W7, but is much more lipophilic and accumulates 
in lipid membranes (see Ovadi, 1989). Equally it is possible that 
the potentiation of the response to dopamine is independent of 
calmodulin, as one would always expect W7 to be less potent if the 
blockade of calmodulin was involved. It may be that longer periods 
of exposure to lower concentrations of calmidazolium should be 
attempted. 
Higher concentrations of the calmodulin antagonists induced a 
hyperpolarization on their own. Figure 53 illustrates the response 
to addition of (A) 100µM W7 and (B) 10µM calmidazolium to the 
superfusate. The hyperpolarization to each compound was close to 
the maximum (- 110mV) obtained to dopamine under these conditions 
(KC1 1mM, see Ginsborg et al, 1974). The period of exposure 











FIGURE 52 Potentiation by W7 and by calmidazolium of the 
hyperpolarization induced by locally applied dopamine (500nM; 
35KPa). Al: response to a 50ms pulse of dopamine in the absence 
of W7. A2: hyperpolarization to an identical stimulus in the 
presence of 100nM W7 after a 15min exposure. The resting potential 
was -46mV. BI: control response of a different cell to a 120ms 
pulse of dopamine. B2: response to an identical stimulus in the 
presence of 5µM calmidazolium after a 10min exposure. Resting 
potential -50mV. 
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The hyperpolarizing response to W7 and to 
calmidazolium. A: the hyperpolarization to 100µM W7. W7 was in 
contact with the preparation for 7min before the onset of the 
response. The resting potential was -32mV. B: the 
hyperpolarization of a different cell to 10µM calmidazolium. This 
compound was in contact with the preparation for 5min before the 
onset of the response. Resting potential was -36mV. In each case 
the arrow marks the begining of the wash. 
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response was almost immediate (30 s), while in the majority of cases 
no effect was observed until 5 -15 min after addition of these 
compounds to the solution. Figure 53.1 shows the response of a 
cell to 100µM W7 on an expanded time scale. This illustrates the 
slow onset of the response and slow decline on the removal of W7 
from the superfusate. Variations in the time of onset of the 
response probably reflect variations in barriers to diffusion from 
the bathing solution to the cell being studied. 
To investigate the possibility that the hyperpolarizing response to 
W7 was mediated by dopamine receptors, the effect of the D1 
antagonist SCH23390 on the hyperpolarization to W7 was studied. 
Figure 54 shows a sub - maximal hyperpolarization to 50µM W7 obtained 
(A) in the absence and (B) in the presence of 50µM SCH23390. One 
can see that after a 30 min exposure to the D1 antagonist the 
response to W7 was unaffected. As would be expected from the 
studies in Chapter II, SCH23390 abolished a dopamine- induced 
hyperpolarization equal in amplitude to that induced by W7. 
Similar results were obtained in two other experiments. It may 
thus be concluded that the calmodulin antagonists have a post - 
synaptic action independent of the dopamine receptor. In addition 
the greater potency of calmidazolium than that of W7 suggests that 
inhibition of calmodulin may underlie the hyperpolarization. 
Ginsborg et al (1980) established that the hyperpolarization to 
dopamine was a calcium- dependent event, which probably relies, at 
least in part, on the release of calcium from intracellular stores. 
Thus it seemed important to investigate whether or not the 





FIGURE 53.1 The hyperpolarizing response to 100 uM W7. W7 was 
in contact with the preparation for 7 min before the onset of the 
response. The resting potential was - 32 mV. The arrow marks the 




FIGURE 54 The effect of SCH23390 on the hyperpolarization 
induced by W7. A: the response to 50µM W7 in antagonist free 
solution. B: the response to an identical stimulus in the 
presence of 50µM SCH23390 after a 30min exposure. The resting 
potential was -52mV. In A and B the arrow marks the beginning of 
the wash. In each case W7 was in contact with the preparation for 
30s before the onset of the response. 
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the release of calcium from the same cellular source as that 
accessed by dopamine. Figure 55 shows the hyperpolarization evoked 
by W7 in the absence of added extracellular calcium. As can be 
seen, the response to W7 declined after about 60 min. Similar 
results were obtained in one other experiment. In the presence of 
extracellular calcium, responses to W7 appear to be sustained 
indefinitely (n = 7). Thus the decline of the response in the 
absence of added calcium may be attributed to the depletion of an 
intracellular calcium store. This store appears to be the same as 
that accessed by dopamine as is illustrated in figures 56 and 57. 
Figure 56A shows the control response to 100µM W7 in the presence of 
external calcium. The superfusate was then changed to one free of 
added calcium and the preparation washed in this solution for 
10 min. A supramaximal concentration (100µM) of dopamine was then 
added to the superfusate in order to deplete the calcium store. 
The hyperpolarization induced and subsequent decline of the response 
to zero is shown in figure 56B. This decline indicates a fall in 
cytoplasmic calcium concentration and, as dopamine was present 
throughout, the depletion of the calcium source. The superfusing 
fluid was then changed to one which contained 100µM W7, but no added 
calcium or dopamine. Figure 56C showed that this solution had no 
effect on the membrane potential. Thus following the depletion of 
the source of calcium on which the response to dopamine was 
dependent, no further response could be obtained to W7. The 
response to W7 and to dopamine recovered on readmission of calcium 
to the superfusate. Similar results were obtained in four other 
experiments. It would appear therefore that the hyperpolarization 
to W7 is calcium- dependent and relies on the same source of calcium 
as does dopamine. This conclusion is supported by the finding that 
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20mV 
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FIGURE 55 The hyperpolarization induced by 100pM W7 in the 
absence of external calcium after a 10min exposure to calcium free 
solution (no EGTA added). W7 was in contact with the preparation 











FIGURE 56 The abolition of the response to W7 by prior 
stimulation with dopamine in the absence of external calcium. A: 
the hyperpolarization induced by 100µM W7 in the presence of 
calcium. W7 was in contact with the preparation for 30s before the 
onset of the response. B: the hyperpolarization to 100µM dopamine 
with calcium absent after a 10min exposure to calcium free solution 
(no EGTA added). Note the decline of the response to the resting 
potential level in the presence of dopamine. C: the effect of 
subsequent superfusion of 100µM W7 with calcium still absent. In A 
and B the arrow marks the begining of the wash. These responses 
were taken from a continuous recording from a single cell. The 
resting potential was -4SmV. In A and C the arrow marks the 
beginning of the wash. 
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exposure of the preparation to W7 in the absence of calcium reduces 
the response to dopamine. Figure 57A shows the response to 100µM 
dopamine in the presence of calcium. The preparation was then 
washed for 10 min in calcium free solution. Figure 57B shows the 
response to 10001 W7 with calcium still absent. Figure 57C shows 
the subsequent response to 100µM dopamine after the removal of W7 
from the superfusate. The preparation was then washed first with 
calcium containing solution for 20 min and then with solution 
containing no added calcium for a further 10 min. Dopamine (100µM) 
was then readmitted to the superfusate (figure 57D). Comparison of 
parts C & D of figure 57 clearly shows that prior application of W7, 
in the absence of calcium, reduces the calcium -free response to 
dopamine. It is also of interest to note that while the calcium 
free response to dopamine declines rapidly, that to W7 is sustained 
over a prolonged period (see figures 55 and 57D). 
A study was also made of the effect of prolonged exposure to W7 on 
submaximal responses to locally applied dopamine. After up to 
30min in 100µM W7, submaximal responses to dopamine were 
potentiated, as would be expected from the effect of low 
concentrations of W7 on the response to dopamine (see figure 52A). 
However, after a more prolonged exposure to W7 subsequent responses 
to dopamine were inhibited as shown in figure 58. A shows a 
control response to locally applied dopamine (5 x 10 -7M, 35kPa). B 
shows the effect of an identical stimulus after 60min exposure to 
100µM W7 and a washout to allow recovery of the resting potential. 







FIGURE 57 The inhibition of the response to dopamine by prior 
stimulation with W7 in the absence of calcium. A: the response 
induced by 100µM dopamine in the presence of calcium. B: the 
response to 100µM W7 with calcium absent after a 10min exposure to 
calcium free solution (no EGTA added). W7 was in contact with the 
preparation for 6min before the onset of the response. In A and B 
the arrows mark the beginning of the wash. C: the effect of 
subsequent superfusion of 100µM dopamine with calcium still absent. 
D: the response to 100µM dopamine in calcium free solution after 
exposure to normal calcium containing solution for 20 min. All 
five responses were taken from a continuous record from a single 
cell. The resting potential was -40mV. 
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FIGURE 58 Desensitization of the acinar cells to locally 
applied dopamine (500nM; 35KPa) by prolonged exposure of the 
preparation to W7. A: the hyperpolarization induced by a 100ms 
pulse of dopamine before exposure to W7. B: the effect of a 100ms 
pulse of dopamine after a lh exposure to 100µM W7. C: subsequent 




The effects of two calmodulin antagonists, W7 and calmidazolium, on 
the secretory responses of the cockroach salivary gland to dopamine 
have been described. It was shown that W7 and calmidazolium 
induced secretion at low concentrations, but inhibited the secretory 
response to dopamine at higher concentrations. 
One possible explanation for these apparently paradoxical findings 
is that that there are two parallel secretory mechanisms, both being 
calcium- dependent, but only one being calmodulin- dependent. 
Inhibition of calmodulin, since the electrophysiological data 
suggests that this would increase the level of free calcium within 
the cell, would therefore activate the calmodulin- independent 
component of secretion, but prevent any calmodulin- dependent 
contribution to secretion. A likely candidate for the regulation 
of the calmodulin- independent pathway is protein kinase -C, which has 
been shown to be an intermediate in secretion from gastric mucosal 
cells (Siedler and Sewing, 1989), platelets (Yamanashi et al, 1983) 
and rat pituitary cells (Das et al, 1989). In preliminary 
experiments D. MacEwen and I have shown that protein kinase -C is 
present in the cytosol of homogenates of cockroach salivary glands, 
but is found in higher concentrations in the particulate fractions 
in homogenates of glands that have been exposed to dopamine. 
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As the affinity of calmodulin for its target proteins varies (see 
Ovadi, 1989), an alternative explanation is that calmodulin 
antagonists inhibit selectively one calmodulin- dependent event, such 
as calcium sequestration, without affecting another, such as 
secretion. 
Another possibility, namely that W7 and calmidazolium are partial 
agonists of the dopamine receptor, is highly unlikely, as to my 
knowledge they are without agonist or antagonist activity at cell 
surface receptors (see also Geitzen et al, 1981; Ovadi, 1989). 
Electrophysiology 
In contrast to their effects on secretion, the calmodulin 
antagonists were stimulatory with respect to the electrical response 
of the salivary gland acinar cells. Thus low concentrations of 
these compounds potentiated the hyperpolarization to dopamine, while 
higher concentrations of W7 and calmidazolium hyperpolarized the 
acinar cells on their own. Additional studies with W7 established 
that the hyperpolarization resulted from a post- synaptic action 
independent of dopamine receptor activation, as SCH23390 failed to 
inhibit a sub -maximal response. Furthermore, the hyperpolarization 
to W7 was found to rely on the release of calcium from the same 
cellular source as that accessed by dopamine, as depletion of the 
calcium store by dopamine or by W7 inhibited any further response to 
either compound. This suggests that W7 and calmidazolium inhibit a 
process which opposes increases in cytosolic calcium levels at rest. 
It seems likely that this process is calmodulin- dependent as 
163 
calmidazolium was more potent in this respect than was W7. 
Moreover the concentrations used were within the range known to 
inhibit calcium -calmodulin- dependent processes (see introduction). 
Model 
It is proposed that calmodulin, on combining with calcium, activates 
systems which reduce cytoplasmic free calcium concentration. 
Figure 59 illustrates a more complex model in which calmodulin- 
independent processes coupled to protein kinase -C are incorporated. 
It is postulated that in the resting cell the concentrations of free 
and bound calcium are in dynamic equilibrium. IP3, which is 
present in high concentrations within the acinar cells at rest and 
may be an intermediate in the hyperpolarization to dopamine (see 
Chapter IV), promotes an increase in free calcium, and 
calmodulin /protein kinase -C promotes a decrease. Inhibition of 
calmodulin /protein kinase -C would evidently result in an increase in 
free calcium and hence a hyperpolarization. It is also of interest 
to note that with appropriate kinetic parameters the model would be 
expected to give rise to oscillations in free calcium concentration 
since the system has both positive and negative feedback. Although 
calcium oscillations such as occur in hepatocytes (Woods et al, 
1987; Walker et al, 1986), pituitary gonadotrophes (Shanghold, 
1988) and endothelial cells (Jacob et al, 1988) have not been 
observed in the cockroach salivary gland acinar cells, the 
oscillations seen in the hyperpolarizing response to dopamine 
suggest their existence (see figures 34 & 57A). In general, upon 
agonist- induced calcium release, the oscillations are maximal once 
the threshold for release is breached, the frequency of the 
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oscillations increasing as the agonist concentration is increased 
(Berridge, 1988; Rink and Jacob, 1989). Woods et al (1987) 
suggested that calcium- mediated inhibition of phospholipase -C and 
the subsequent reduction in IP3 may be responsible for the 
oscillations. However, this theory was abandoned when 
intracellular injection of a stable analogue of IP3 was shown to 
induce oscillations (Berridge, 1988; Parker and Miledi, 1986; 
Capoid et al, 1987; Wakui et al, 1989). The model currently 
favoured relies on the existence of two separate non -mitochondrial 
calcium stores, one 
The calcium released 
for release from the 
insensitive and the other sensitive to IP3. 
from the IP3- sensitive pool acts as a stimulus 
pool insensitive 
Goldbeter et al, 1990). 
to IP3 (Thevenod et al, 1989; 
The existence of oscillations in this 
model relies upon the complete depletion of an IP3 sensitive pool 
and its subsequent replenishment by transmembrane influx of calcium. 
It is postulated that during replenishment no calcium release from 
the IP3 - sensitive pool, and hence from the IP3- insensitive pool, can 
occur until a threshold concentration of stored calcium is reached. 
During this period, the free calcium concentration falls. Against 
this idea is the finding that oscillations can be generated by 
direct intracellular injection of calcium or by calcium influx 
stimulated by the ionophore A23187 (Osipchucka et al, 1990). The 
model proposed here (see Figure 59) would be expected to result in 
oscillations in all the circumstances in which they have been 
observed, namely on stimulation of cell surface receptors, G- protein 
activation, microinjection of IP3 and of calcium, and calcium influx 
induced by the ionophore A23187. 
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Calmodulin- dependent processes The underlying mechanism relies 
on the reduction of intracellular free calcium by three separate 
calmodulin- dependent processes, namely (A) activation of IP3 kinase 
(Colca et al, 1988; Morris et al, 1987; Ryu et al, 1987; Biden et 
al, 1987; Tallant and Wallace, 1985), (B) activation of plasma 
membrane calcium pumps (James et al, 1989; Enyedi et al, 1989; 
Eggermont et al, 1989; Petruniaka et al, 1989) and (C) activation 
of calcium pumps in the endoplasmic reticulum (Eggermont et al, 
1989; James et al, 1989; Wegener et al, 1986; Burgoyne et al, 
1989). They evidently imply that an increase in calcium 
concentration by activating calmodulin may reduce the concentration 
of IP3 and increase the rate of calcium sequestration. These 
processes would be inactivated as the calcium level falls, allowing 
a subsequent rise and thus oscillations. 
Calmodulin- independent processes Although the findings of the 
present investigation together with those of other workers support 
such a negative feedback, it is unlikely that the calcium -calmodulin 
complex is solely responsible. Other candidates include calcium 
activated protein kinase -C which has been shown to close calcium 
channels (Marchetti and Brown, 1988; Limas, 1980) induce the 
metabolism of IP3 by IP3 phosphatase (Connolly et al, 1986; 
Nishizuka, 1986) and which may also be an activator of endoplasmic 
reticulum calcium ATPase (Petruniaka et al, 1989). As mentioned 
above (p.160) protein kinase -C is present in the gland and both 

























































































































































































































































































































































The calcium- mediated inhibition of phospholipase -C (Woods et al, 
1987) may also be of some importance to such a negative feedback, 
but the inhibition of phospholipase -C is unlikely to be inhibited by 
either of the calmodulin antagonists. 
Desensitization 
As shown by Ginsborg and House (1976) prolonged exposure to high 
concentrations of dopamine causes desensitization of the electrical 
response to dopamine; from the results reported on page 158, it 
appears that W7 also desensitizes the electrical response to 
dopamine. Since both dopamine and W7 act by increasing cytoplasmic 
calcium it is tempting to suppose that this latter process plays a 
significant role in desensitization. One possible mechanism not 
directly involving the dopamine receptors themselves is the 
induction of enzymes that reduce intracellular free calcium. Since 
desensitization occurs relatively rapidly (complete in less than 60 
min) this does not seem a very strong possibility. The same 
consideration makes receptor down- regulation unattractive 
possibility, while receptor sequestration is not considered to be 
important in the desensitization of G- protein coupled receptors. 
The most likely process would appear to be calcium- dependent 
phosphorylation of the dopamine receptor, conceivably by protein 
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APPENDIX I 
Drugs and chemicals 
Dopamine (3- hydroxy tyramine HC1), haloperidol (4-[4-(4 - 
chlorophenyl)-4- hydroxypiperidino ] -4'- fluorobutyrophenone), 
calmidazolium (compound R24571; (l-[bis(4-chlorophenyl)- methyl] -3- 
[2-(2,4- dichlorophenyl)- 2- [(2,4- dichlorophenyl)- methoxyl]- ethyl] -1H- 
imidazolium chloride)) and W7 (N-(6- aminohexyl) -5- chloro -l- 
naphthalene sulphonamide) were obtained from SIGMA (Poole, Dorset, 
U.K.). Chlorpromazine (2- chloro- l0 -(3- 
dimethylaminopropyl )phenothiazine HC1) was obtained from Aldrich 
Chemical Company (Gillingham, Dorset, UK). ( ±)Sulpiride (5- 
(aminosulphonyl)-n-[(l- ethyl- 2- pyrrolidinyl)methyl] -2- 
methoxybenzamide) was obtained from Semat (St. Albans, Herts. UK). 
SCH23390 (8- chloro -2,3,4,5 - tetrahydro -3- methyl -5- phenyl -lH -3- 
benzazepine-7-ol maleate) was a gift from Dr. V.G. Daniels, Kirby 
Warrick Pharmaceuticals (Bury St. Edmunds, Suffolk, UK). 
Domperidone (5- chloro- l- {1- [3 -(2- oxobenzimidazolin -l- yl)propyl] -4- 
piperidyl}]benzimidazolin -2 -one) was a gift from Janssen 
Pharmaceutical (Marlow, Bucks, UK). Metoclopramide (4- amino -5- 
chloro-n-(2- diethylaminoethyl )- 2- methoxybenzamide HC1) was a gift 
from Beecham Pharmaceuticals (Harlow, Essex, UK). Quinpirole 
( trans- (- )- 4aR- 4,4a,5,6,7,8,8a,9- octahydro- 5- propyl -2H- pyrazolo- 
(3,4- g)quinoline monohydrochloride) and LY163502 (trans-(-) - 
5,5a,6,7,8,9,9a,10- octahydro- 6- propylpyrimido[4,5- g]quinolin -2 -amine 
dihydrochloride dihydrate) were donated by Lilly laboratories 
(Indianapolis, IN, USA). Fenoldopam (SKF 82526 -J, 6- chloro -7,8- 
dihydroxy-l-(p-hydroxyphenyl)- 2,3,4,5- tetrahydro- (1H) -3- benzazepine) 
was supplied by Dr. J Skidmore, SK &F Laboratories, Welwyn, Herts, 
UK. ( +)SCH23390 (8- chloro- 2,3,4,5 - tetrahydro -3- methyl -5- phenyl -lH- 
3- benzazepin -7 -ol maleate) and SKF 38393 (2,3,4,5- tetrahydro -7,8- 
dihydroxy -l- phenyl -1H -3- benzazepine HC1) were obtained from Semat, 
St Albans, Herts, UK. 
Dopamine was dissolved in lmg m1 -1 ascorbic acid with the final 
dilution being made in physiological saline. The maximum 
concentration of ascorbic acid applied to the preparation was 0.1mg 
m1-1, and when tested alone this had no effect on the preparation. 
Domperidone, ( ±)sulpiride and haloperidol were dissolved in 5mg ml -1 
tartaric acid and dilutions made from this in physiological saline. 
The pH of the solution was adjusted to control values (pH 7.7 -7.8) 
with 1M NaOH; in this condition tartaric acid was found to have no 
effect on the preparation. 
Calmidazolium was dissolved in DMSO and dilutions made from this in 
physiological saline. The highest concentration of DMSO applied to 
the preparation was 1 %, and when applied alone this had no effect on 
the responses to dopamine. 
APPENDIX II 
PROGRAM WRITTEN BY PROFESSOR B.L. GINSBORG 
mark.f 
PROGRAM MARKF 
C PARALLEL DOSE RESPONSE FIT 
C PRINTOUT VERSION NO INTERMEDIATE RESULTS 
C E04CCF EXAMPLE PROGRAM TEXT MODIFIED 
C MARK I1.5(F77) REVISED. NAG COPYRIGHT 1985. 
C .. Parameters .. 
INTEGER N, 1W 
PARAMETER (N= 4,IW =Ns1) 
INTEGER NOUT 
PARAMETER (NOUT =6) 
C ***************************** *l* * * * * * * * * * * * * * * * * * * * *t * * * *t ** 
C 
CHARACTER *12 C1,C2 
C 
C ****************************** ** * ** * * * * * * * **** * * * *s ** **** **t* 
C ARRAYS IN COMMON 
DOUBLE PRECISION T(200), Y(200),TT(200),YY(200) 
C .. Scalars in Coamon .. 
INTEGER IMONIT 
C .. Local Scalars .. 
DOUBLE PRECISION F, R, TOL 
INTEGER I, IFAIL, MAXCAL 
C .. Local Arrays .. 
DOUBLE PRECISION SIM(IW,N), WI(N), W2(N), W3(N), W4(N), W5(IW), 
* X(N) 
C .. External Functions .. 
DOUBLE PRECISION X02AAF 
EXTERNAL XO2AAF 
C .. External Subroutines .. 
EXTERNAL E04CCF, FUNCT, MONIT 
C .. Intrinsic Functions .. 
INTRINSIC SQRT 
C .. Common blocks .. 
COMMON /OUTP /IMONIT 
COMMON Y, T,M,YY,TT,MM 
DOUBLE PRECISION P,KCO,KAN,AMP 
COMMON P,KCO,KAN,AMP 
111 NRITE(6,99990) 
99990 -FORMAT(' HON MANY CONT PAIRS? ') 
READ(5, *) M 
C OBSERVATIONS CONTROL 7 AGONIST 8 
C (I= 1,2,...,M) 
C CONCENTRATION T RESPONSE Y 
C 




OPEN (7, FILE =C1) 





99991 FORMAT(' now MANY ANTAG PAIRS') 
READ(5, *) MM 
DO 11 I = 1,N 
X(I) = 1.0D0 
11 CONTINUE 
WRITE(6,33) 
33 FORMAT(' DATA TO P. FITTED WITH LOGOID') 
34 FORMAT(' CONTROL') 
35 FORMAT(' WITH ANTAG PRESENT') 
WRITE(6,34) 
READ (7, *) (T(1), Y(I),I = 1,M) 
READ(8, *) (TT(I),YY(1),I =1,MM) 





DO 21 1 =1,M 
WRITE(6,19999) TT(1),YY(I) 
21 CONTINUE 
C ** SET IMONIT TO 1 TO OBTAIN MONITORING INFORMATION *** 
IMONIT = 0 
TOL = SORT(X02AAF(R)) 
MAXCAL = 5000 
IFAIL = 0 
WRITE(6,99989) 
99989 FORMAT(' guess values: p ,aaxresponse,ec50cont,ec50ant') 
READ(5, *) P,AMP,KCO,KAN 
CALL E04CCF( N, X, F, TOL, IW, W1, W2, W3 ,W4,W5,SIM,FUNCT,MONIT,MAXCAL, 
* IFAIL) 
WRITE (NOUT,FMT= 99998) F 
WRITE (NOUT,FMT = 99997) P* X(1),KCO *X(2),KAN *X(3),AMP *X(4) 
WRITE ( NOUT,FMT= 99996) IFAIL 
C 
99998 FORMAT (' FINAL FUNCTION VALUE IS ',F16.8) 
99957 FORMAT (' P,KCONT,KANT,AMP',4F16.8) 







DOUBLE PRECISION FC 
INTEGER N 
DOUBLE PRECISION XC(N) - 
INTRINSIC DEXP 
DOUBLE PRECISION T(200), Y(200),TT(200),YY(200) 
INTEGER I 
DOUBLE PRECISION EB, A,B 
COMMON Y, T,M,YY,TT,MM 
DOUBLE PRECISION P,KCO,KAN,PW,KCOW,KANW,AMP,AMPW 
COMMON P,KCO,KAN,AMP 
PW = P *XC(1) 
KCOW = KCO *XC(2) 
KANW = KAN *XC(3) 
AMPW = AMP *XC(4) 
IF ( PW .LE. 0) GO TO 33 
IF (KCOW .LE. 0) GO TO 33 
IF (KANW .LE. 0) GO TO 33 
FC = 0.0 
DO 20 I =1,M 
A= T(I) * *Pk 
FA = (AMPW *A) /(A + KCOW * *PW) - Y(1) 
FC = FC +FA*FA 
20 CONTINUE 
DO 50 I =1,MM 
EB = TT(I)**PW 
B = (AMPW*EB)/(EB + hANW**PW) - YY(I) 











MONIT(FMIN,FMAX,SIM,N,N),NCALL) C .. Parameters .. 
INTEGER NOUT 
PARAMETER (NOUT =6) 
C .. Scalar Arguments .. 
DOUBLE PRECISION FMAX, FMIN 
INTEGER N, N1, NCALL C .. Array Arguments .. 
DOUBLE PRECISION SIM(N1,N) C .. Scalars in Common .. 
INTEGER IMONIT 
C .. Local Scalars .. 
INTEGER 1, J 
C Common blocks .. 
COMMON /OUTP /IMONIT C .. Executable Statements .. 
IF (IMONIT.NE.0) THEN 
WRITE (NOUT,FMT= 99999) NCALL, FMIN WRITE (NOUT,FMT= 99998) ((SIM(I,J),J= 1,N),I =1,N1) END IF 
C END OF PRINT ROUTINE 
RETURN 
C 
99999 FORMAT (' AFTER',I5,' CALLS, F VALUE IS',F16.9,' WI', * 'TH SIMPLEX') 
99998 FORMAT (4(3F12.4,/)) 
END 




















epcf77 -ats -fpa -o marko mark.f -lnag 
EPC Fortran77 /386 Version 2.4.11 (1167) 





163 Lines Compiled 
marko kmdatc kmdata 
HOW MANY CUNT PAIRS? 
7 
HOW MANY ANTAG PAIRS 
7 






















FINAL FUNCTION VALUE IS 374.55377954 
P,KCONT,KANT,AMP 1.28644657 0.09137569 2.18635886 93.74675660 
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Characterization of the dopamine receptor mediating the 
hyperpolarization of cockroach salivary gland acinar cells 
in vitro 
'A.M. Evans & K.L.Green 
Department of Pharmacology, University of Edinburgh, Edinburgh EH8 9JZ 
1 Intracellular recordings have been made of the hyperpolarization of cockroach salivary gland cells 
induced by nerve stimulation and dopamine. 
2 The relative potency of a number of dopamine antagonists in inhibiting the dopamine- and nerve- 
mediated hyperpolarization was studied. SCH23390 (10- 50pM), chlorpromazine (0.1- 5µm), haloperidol 
(10- 100pm) and metoclopramide (1 mM) inhibited the hyperpolarization. 
3 In contrast, domperidone and ( ±)- sulpiride potentiated the hyperpolarization induced by both nerve 
stimulation and dopamine. 
4 Apparent dissociation constants (KO,µµ) were obtained for the blockade of the dopamine- induced 
hyperpolarization. The rank order of potency (KD,pp in parentheses) was as follows: chlorpromazine 
(0.2pm); haloperidol (3.3pm); SCH23390 (4.1pm); metoclopramide (265pm); domperidone and ( ±) -sul- 
piride (inactive). 
5 It is concluded that the receptor subserving the dopamine -induced hyperpolarization of the salivary 
gland acinar cells is the same as that mediating the secretory response to dopamine. In addition these data 
support our findings, which suggested that this receptor is similar to the Dr dopamine receptor, but 
distinct from the D2 receptor found in mammalian systems. 
Introduction 
Stimulation of the suboesophageal nerve evokes secretion 
from the cockroach (Periplaneta americana and Nauphoeta 
cincerea Olivier) salivary gland (Whitehead, 1971; Smith & 
House, 1977), which is accompanied by a hyperpolarization of 
the acinar cells (House, 1973). Previous studies have estab- 
lished that the neurotransmitter involved is dopamine (Bland 
et al., 1973; Fry et al., 1974; Kapoor et al., 1983). Activation of 
the dopamine receptor leads to an increase in a calcium - 
dependent potassium conductance, which underlies the hyper - 
polarizing response (Ginsborg et al., 1974; 1980), and an 
increase in cytosolic adenosine 3':5'- cyclic monophosphate 
(cyclic AMP) (Grewe & Kebabian, 1982) which appears to be 
an intermediate in the secretory, but not the electrical 
response to dopamine (Gray et al., 1984). More recently the 
rank order of potency of a number of dopamine antagonists 
was used to characterize the receptor mediating the secretory 
response of the salivary gland. It was concluded that the 
receptor was similar to the D1 receptor found in the mamma- 
lian CNS and periphery (Evans & Green, 1990). It is therefore 
of some interest to establish whether or not the same order of 
potency is obtained for the receptor mediating the electrical 
response of the acinar cells to dopamine. To enable as direct a 
comparison as possible the present investigation follows 
closely the protocol used in the study of the secretory 
response. Thus the rank order of potency for the selective D1 
antagonist SCH23390, the selective D2 antagonists domperi- 
done, ( ±)- sulpiride, haloperidol and metoclopramide (for 
review see Clark & White, 1987), and the non -selective dopa- 
mine antagonist chlorpromazine (O'Boyle & Waddington, 
1984) was obtained. The results suggest that the receptor 
mediating the dopamine- induced hyperpolarization is the 
same as that mediating the secretory response to dopamine, 
and is similar to the D1 receptor found in mammalian 
systems. 
Author for correspondence. 
Methods 
Paired salivary glands and associated ducts were dissected 
from adult cockroaches (Nauphoeta cinerea Olivier) as 
described previously (House, 1973). The preparation was 
pinned to the base of a shallow perspex chamber lined with 
silicone resin (Sylgard, Dow Corning). The main ducts of the 
gland were drawn into a suction electrode to allow stimu- 
lation of the encapsulated suboesophageal nerve. The pre- 
paration was kept at room temperature (18 -25 °C) and 
perfused at a rate of 5mlmin' with a solution of the follow- 
ing composition (mM): NaCl 160, CaC12 5, KC1 1, glucose 20, 
Tris buffer 2.5, pH adjusted to between 7.70 and 7.80 with 
HC1. Recording microelectrodes were filled with 3m KC1 and 
had resistances between 20 and 40 M. Membrane potentials 
were recorded on a pen recorder (Gould, Brush 220) and on 
video tape (Sony SL -F 30; with a digital audio processor, 
Sony PCM -701 ES) via a pre- amplifier (Dagan 8900 patch 
clamp). Sub -maximal responses to nerve stimulation were 
obtained with a train of 1 -10 impulses, 0.5 ms pulse width, 
1 -100 V, 20 Hz. Dopamine (500 nM) was applied to the prep- 
aration locally by pressure ejection from a broken microelec- 
trode (pulse of 35 kPa, 0.003 -5 s; Picospritzer II, General 
Valve Corporation). An interval of 90 s was allowed between 
any two stimuli. Antagonists were added to the perfusate after 
four consistent control responses had been obtained to each 
stimulus applied. 
Estimation of apparent KD values 
When applied by pressure ejection the absolute concentration 
of the agonist at the acinus is, of course, unknown and a func- 
tion of time. However, it was assumed that the effective con- 
centration of agonist at the acinus was proportional to the 
duration of a pulse of fixed pressure (McCaman et al., 1977; 
Sakai et al., 1979). This assumption was supported by the fact 
that over a considerable range of pulse durations, the 
1og10- duration response curve was linear (Figure 1). Therefore, 
throughout the present investigation the duration of the pres- 
sure pulse used for agonist application, and not agonist con- 
centration, was used in the estimation of dose -ratios. 
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Figure 1 Dose -response curve for the dopamine -induced hyper - 
polarization of the cockroach salivary gland cells. The results are from 
a single experiment. Dopamine was applied by pressure ejection 
(35 kPa; duration of pulse as shown). The inset shows the experimen- 
tal record, with the duration of the pulse marked below each response. 
Recordings of the membrane potential were made intracellularly. The 
initial resting potential was - 55 mV. In this and all subsequent 
records the hyperpolarization is downwards. 
The rate of equilibration of all active antagonists studied 
was inconsistent and often full equilibration was not obtained 
even during incubations of up to 1 h, with the dose -ratio 
increasing during this period. These considerations make it 
impossible to determine absolute values for the KID . However, 
it seemed likely that useful estimates (at least for comparative 
purposes) would be obtained from the increase in stimulus 
required, after a fixed period of incubation in the presence of 
the antagonist, to match a response in antagonist -free solu- 
tion. This assumption seems justified by the degree of agree- 
ment between the results in this paper and those obtained by 
more conventional methods in relation to the secretory 
response of this gland (Evans & Green, unpublished 
observation). 
In practice, values for the apparent KD (KD,,,) were 
obtained from `dose- ratios' estimated in a `three point assay' 
(Edinburgh Staff, 1968); the time of exposure to the antagonist 
was 30 min. The antagonists studied were: SCH23390 (1- 
100pM); chlorpromazine (0.1-5 pm); haloperidol (1-100 pm); 
metoclopramide (0.1 -1 mM); ( ±)- sulpiride (1-100 pm); dom- 
peridone (1- 100pM). Dose -ratios were estimated independent- 
ly on separate preparations for three concentrations of each 
antagonist (except metaclopramide; see results). A separate 
value for the logro KD. was estimated for each experiment 
(see Waud & Parker, 1971), and the geometric means of the 
Kr., together with confidence limits was calculated (Sokal & 
Rohlf, 1969). 
Drugs and chemicals 
Dopamine (3- hydroxytyramine HCl) and haloperidol (4-[4-(4 - 
chlorophenyl) - 4 - hydroxypiperidino] - 4' - fluorobutyro - 
phenone) were obtained from Sigma (Poole, Dorset). Chlor- 
promazine (2 - chloro -10 - (3 - dimethylaminopropyl)pheno - 
thiazine HCl) was obtained from Aldrich Chemical Company 
(Gillingham, Dorset). ( ±)- Sulpiride (5-(aminosulphonyl)-n-[(1- 
ethyl -2 - pyrrolidinyl)methyl] -2 - methoxybenzamide) was 
obtained from Semat (St Albans, Herts). SCH23390 (8-chloro- 
2,3,4,5 -tetrahydro- 3 -methyl- 5- phenyl - IH- 3- benzazepine -7 -ol 
maleate) was a gift from Dr V.G. Daniels, Kirby Warrick 
Pharmaceuticals (Bury St Edmunds, Suffolk). Domperidone 
(5 - chloro - 1 - {1 - [3 - (2 - oxobenzimidazolin - 1 - yl)propyl] -4 - 
piperidyl }]benzimidazolin -2 -one) was a gift from Janssen 
Pharmaceutical (Marlow, Bucks). Metoclopramide(4- amino- 
5- chloro -n -(2- diethylaminoethyl) -2- methoxybenzamide HC1) 
was a gift from Beecham Pharmaceuticals (Harlow, Essex). 
Dopamine was dissolved in ascorbic acid l mg I, with 
the final dilution being made in physiological saline. The 
maximum concentration of ascorbic acid in the ejection 
pipette was 0.1 mg m1 -1, and when tested alone this had no 
effect on the preparation. 
Domperidone, ( ±)- sulpiride and haloperidol were dissolved 
in tartaric acid, 5 mg m1 -', and dilutions made from this in 
physiological saline. The pH of the solution was adjusted to 
control values (pH 7.7 -7.8) with 1 M NaOH; in this condition 
tartaric acid was found to have no effect on the preparation. 
Results 
Stimulation of the suboesophageal nerve evokes a stimulus - 
dependent hyperpolarization of the cockroach (Nauphoeta 
cinerea Olivier) salivary gland acinar cells in vitro, which is 
occasionally followed by a depolarization (House, 1973). 
When applied locally by pressure ejection, dopamine mim- 
icked the effect of nerve stimulation in a concentration -related 
manner (Figure 1). It should be noted that throughout this 
study the external potassium concentration was i mm. Thus it 
was not unusual for the hyperpolarization induced by dopa- 
mine to exceed a potential of 100 mV (see House, 1973; Gins - 
borg et al., 1974). 
The effects of SCH23390, haloperidol, chlorpromazine 
and metoclopramide 
At high concentrations some of the antagonists had non- 
specific effects. The inhibition of the hyperpolarization by 
chlorpromazine at concentrations > 5pM was insurmountable, 
while SCH23390 destabilized the acinar cells membrane at 
concentrations c 100pM. It was necessary therefore to study 
the effect of these compounds over a limited concentration 
range. 
SCH23390 (10- 50pM), chlorpromazine (0.1 -5pM), haloperi- 
dol (10- 100pM) and metoclopramide (1 mm) blocked the 
hyperpolarization induced by both dopamine and nerve 
stimulation. The onset of inhibition of the response to dopa- 
mine was immediate, while in the case of nerve stimulation 
there was a delay of between 3 -10 min. This is illustrated in 
Figure 2 which shows a typical record of the onset of block- 
ade following addition of SCH23390 (50pM) to the bath solu- 
tion. 
Nerve stimulation 
Figure 3 illustrates the action of the antagonists on the 
response to nerve stimulation. Figure 3a (i) shows a control 
response; (ii) shows the response after addition of SCH23390 
(20pM) to the perfusate; (iii) shows the effect of increasing the 
number of impulses in the train on the response after the 
onset of blockade; and (iv) shows the degree of recovery on 
washing. Parts b, c and d of Figure 3 illustrate the corre- 
sponding results for chlorpromazine (5 pm), haloperidol 
(20pM) and metoclopramide (1 mì). The inhibition of the 
DA N. St DA N St DA N St 
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Figure 2 The time course for blockade of the hyperpolarization 
induced by locally applied dopamine (DA; 35 kPa; 10 ms) and nerve 
stimulation (NSt; 100 V; 20Hz; 0.5 ms pulse width; 2 impulses in the 
train) respectively, following addition of SCH23390 (50µM); (b) is con- 
tinuous with (a). The initial resting potential was -42 mV. 













4 8 4 40 s 
-42 mV- r -t 
II 
2 5 2 
d 
-55 mV 
10 10 50 10 
Figure 3 The blockade of the hyperpolarization induced by nerve stimulation following addition of (a) SCH23390 (20µM), (b) 
chlorpromazine (5µM), (c) haloperidol (20µM) and (d) metoclopramide (1µM). (i) Control response to nerve stimulation (100 V; 20 Hz; 
0.5 ms pulse width; number of impulses in the train as indicated below each response), (ii) response following the addition of the 
antagonist, (iii) the effect of increasing the number of impulses in the train after 30 min incubation with the antagonist and (iv) 
recovery following a 30 min wash. The initial resting potential for each experiment was as shown. 
response by SCH23390 (10-50 pm) and chlorpromazine (0.5- 
5 µm) was readily surmounted and was reversed on washing, 
although full recovery was not always obtained. In contrast, 
the blockade of the hyperpolarization by haloperidol (10- 
100µM) and metoclopramide (1 mM) was insurmountable, and 
the inhibition by the former was not reversed on washing. The 
inhibition of the response to dopamine by these compounds 
was found to be surmountable and was reversed on washing 
(see below). Thus haloperidol and metoclopramide must have 
an additional presynaptic action. 
Dopamine 
As stated in the methods, a more quantitative analysis of the 
effects of the antagonists was undertaken with respect to the 
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Figure 4 The blockade of the dopamine -induced hyperpolarization by (a) SCH23390 (20pM), (b) chlorpromazine (5pM), (c) haloperi- 
dol (20pM) and (d) metoclopramide (1 mM). (i) Paired, submaximal control responses to dopamine (DA; 35 kPa; duration of pulse in 
ms as shown), (ii) the larger of the two control responses following addition of the antagonist, (iii) response to increased duration of 
dopamine application after a 30 min incubation, and (iv) the degree of recovery of the response following a 30 min wash. The initial 
resting potential for each experiment is shown. 
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Table 1 Dose -ratios estimated by `three point assay' for each of the active dopamine antagonists together with the geometric mean 






















































Metaclopramide 1000 3.90 
1000 3.50 
1000 2.30 264.66 0.03 21.80 
1000 16.60 
`three point assay' for SCH23390 (20µM): (i) shows two differ- 
ent sub -maximal responses to dopamine in the absence of the 
antagonist; (ii) shows the inhibition of the larger of the two 
control responses by SCH23390 (20 pm); (iii) demonstrates 
that increasing the duration of the pressure pulse surmounts 
the blockade; and (iv) shows the degree of recovery on 
washing. Figure 4 sections b, c and d illustrates the corre- 
sponding results for chlorpromazine (5 pM), haloperidol 
(20pM) and metoclopramide (1 mM). In contrast to nerve 
stimulation, the inhibition of the dopamine -induced hyperpo- 
larization by all of these antagonists could be surmounted and 
reversed on washing, although as with nerve stimulation full 
recovery was not always obtained. The dose -ratio for the 
antagonists was calculated in each experiment, and these, 
together with the geometric mean of the apparent KD (KD.o,) 
with 95% confidence limits are shown in Table 1. The rank 
order of potency obtained from these data was as follows 
(IC, in parentheses): chlorpromazine (0.2pM) > haloperidol 
(3.3 pM) = SCH23390 (4.1 pM) > metoclopramide (265 pM). 
The effect of ( ±)- sulpiride and domperidone 
( ±)- Sulpiride (1- 100pM) and domperidone (1- 100pM) failed 
to antagonize the hyperpolarization induced by either dopa- 
mine or nerve stimulation. On the contrary, higher concentra- 
tions of ( ±)- sulpiride (100pM) and domperidone (50 and 
100pM) produced an immediate potentiation of the hyper - 
polarization induced by both dopamine and nerve stimu- 
lation, which was readily reversed on washing. A more 
detailed analysis of the effects of domperidone will be 
published elsewhere. 
Discussion 
Both exogenously applied dopamine and stimulation of the 
suboesophageal nerve induce a hyperpolarization of the cock- 
roach salivary gland acinar cells, which is occasionally fol- 
lowed by a depolarization (House, 1973; Blackman et al., 
1979). Of the antagonists studied chlorpromazine, SCH23390, 
haloperidol and metoclopramide inhibited the hyperpolar- 
ization induced by both dopamine and nerve stimulation, 
while ( ±)- sulpiride and domperidone did not. For each of the 
effective antagonists the onset of the blockade of nerve stimu- 
lation was slower than that for exogenous dopamine. This has 
been reported previously in relation to the action of a- 
flupenthixol by House (1980). He concluded that the receptors 
located at the synapse are deeper within the acinus than those 
activated by the exogenously applied agonist. This may offer a 
further barrier to diffusion, resulting in the delayed onset of 
blockade. 
The rank order of potency for the blockade of the hyper - 
polarizing response to locally applied dopamine was: chlor- 
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Table 2 Comparison of the rank order of potency of dopamine antagonists against the hyperpolarizing and the secretory response of 





Antagonist rank order of potency 
a -Flu >_ Cpz > Phen > SCH = Halo > Met > ( ±) -Sulp = Domp 
(< 500 nM) (215 nM) (1µM) (4.1 pm) (3.8µM) (265pM) (> 100µM) 
a -Flu > Cpz > Phen > SCH > Halo > Met > ( ±) -Sulp = Domp 
(3.3nM) (0.2pM) (1µM) (2.2µM) (17.5pM) (1.2mM) ( >100pM) 
Values in parentheses are the Kw except a- flupenthixol and phentolamine which represent the absolute KD. 
a -Flu = a- flupenthixol; Cpz = chlorpromazine; SCH = SCH23390; (±)-Sulp = ( ±)- sulpiride; Domp = domperidone; Halo = halo- 
peridol; Phen = phentolamine; Met = metoclopramide. 





























pz Col Hal SCH Met 
Antagonist 
Figure 5 The range of logea KD,,, for each antagonist studied. 
Cpz = chlorpromazine; Hal = haloperidol; SCH = SCH23390; 
Met = metoclopramide. 
promazine > haloperidol = SCH23390 > metoclopramide 
(inactive) ( ±)- sulpiride and domperidone. As illustrated in 
Figure 5, there is a considerable scatter between KD s obtained 
from individual experiments, yet there is a clear separation 
between chlorpromazine, haloperidol and SCH23390, and 
metoclopramide. In Table 2 the rank order of potency 
obtained in this study, extended by the addition of phentola- 
mine and a- flupenthixol (Bowser -Riley et al., 1978; House & 
Ginsborg, 1976), is compared with that obtained for the secre- 
tory response to dopamine (Evans & Green, 1990). Thus, in 
contrast to the view of Gray and co- workers (1984), it would 
appear that a single receptor subserves both the hyperpolar- 
ization and the secretory response to dopamine. This receptor 
has an antagonist rank order of potency similar to the D1 but 
distinct from the D2 dopamine receptor found in the mamma- 
lian CNS and periphery (Hilditch & Drew, 1985; Anderson et 
al., 1985; Seeman et al., 1987). The similarity between the 
receptor on the cockroach salivary gland and the D1 receptor 
in mammalian systems is most evident from the fact that the 
selective D1 receptor antagonist SCH23390 inhibits the 
response to dopamine, while the selective D2 antagonists 
domperidone and ( ±)- sulpiride do not. Although haloperidol 
and metoclopramide, which are also selective D2 antagonists, 
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